



Helping all people
live healthy lives

2007 Annual Report



BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

Financial Highlights

Thousands of dollars, except per share amounts

	2007	2006	Change
Operating results			
Revenues	\$6,359,708	\$ 5,738,017	10.8%
Income from continuing operations	\$ 856,167	\$ 815,110	5.0%
Diluted earnings per share, from continuing operations	3.36	3.18	5.7%
Dividends per common share	.98	.86	14.0%

To our shareholders: At BD, our purpose – *“Helping all people live healthy lives”* – serves as the basis for all that we do, and it motivates our 28,000 associates around the world who know that they are making a real difference in improving healthcare, changing medical practice and saving lives. We are doing this while delivering excellent value to our shareholders.

Fiscal 2007 was another successful year for BD. I am pleased to report that we exceeded our financial and operational performance expectations, and showed solid improvement over 2006. Our strong revenue and earnings growth and our positive outlook for fiscal 2008 give us continuing confidence that our strategy is sound. Our implementation is both disciplined and effective. Fiscal 2007 marks the end of the eighth year of leadership for our current executive team – a time during which BD’s revenue and profit base has more than doubled.

We will continue to implement our strategy of increasing sustainable revenue growth through innovation, complemented by driving operating effectiveness and productivity to accelerate our progress. This strategy rewards both customers and shareholders. Our revenue and profit growth will enable us to advance toward our vision of becoming a “great company” – one that achieves great performance for customers and shareholders, makes great contributions to society and is a great place to work.

BD is a complex institution, comprised of three major segments with over a dozen units in about 50 countries. However, a much smaller number of focused strategies target specific opportunities to improve human healthcare. Over our 110-year history, BD has been most successful when we identify underappreciated or emerging healthcare needs, apply technology to solve the problems, use our manufacturing expertise to make high-quality products available and affordable to people around the world, and surround the products with outstanding service and support. This was the case when BD developed the first syringe designed for insulin injection in 1924, pioneered the development of safety-engineered devices designed to protect healthcare workers, and more recently, when we identified addressing healthcare-associated infections as a core focus area for BD’s future growth.

In this letter, I will provide an update on strategic developments, financial performance, social responsibility initiatives, organizational progress, and management and Board developments.



Edward J. Ludwig
Chairman, President and Chief Executive Officer

Great contributions through strategic acquisitions

This year, BD successfully integrated GeneOhm, which was acquired in 2006. The BD GeneOhm platform positions BD to play a leadership role in the prevention of healthcare-associated infections and to lead the evolution from “growth-based” to “molecular-driven” microbiology.

We also completed the TriPath acquisition, expanding our position in cancer diagnostics. Our strategy is to improve the clinical management of cancer through innovative biomarker solutions. We believe TriPath positions BD to have significant impact in the marketplace and to advance cancer treatments through more accurate and earlier detection.

I invite you to read more about our progress in both of these areas in the feature pages that follow.

Great financial and operational performance

Our financial results confirm that our strategy is working. Company revenues of \$6.36 billion represent an increase of 11 percent (reflecting an overall estimated 3 percent favorable impact from foreign currency translation that affected all segments). Our gross profit margin increased 40 basis points to 51.7 percent.

Gross margin improvements resulted from our favorable product mix (higher-value products) and our ongoing efforts to drive productivity. Tools associated with continuous improvement—among them Six Sigma, Lean and Validation—are being used Company-wide. The gross margin improvements in fiscal 2007 more than offset manufacturing start-up costs. Our focus on achieving higher levels of operational effectiveness has resulted in improved quality, global affordability of our products and excellent service levels for our customers.

Adjusted operating income increased approximately 13 percent from 2006. Adjusted operating margin as a percentage of sales improved from 20.5 percent to 20.8 percent, reflecting improved gross profit margin and SSG&A leverage.*

BD is committed to a very strong return of cash to our shareholders. This year, we generated over \$1.2 billion in operating cash flow. We returned over 56 percent (or \$690 million) of our operating cash flow to shareholders. We repurchased nearly 6 million common shares for \$450 million and paid dividends of \$240 million. On November 20, 2007, our Board of Directors voted to increase the annual dividend by 16.3 percent to \$1.14. This marks the 35th consecutive year of dividend increases for the Company. Our balance sheet remains strong and liquid, enabling future strategic investments. BD's three-year average return on invested capital increased to 30.8 percent in 2007 from 29.0 percent in 2006.

BD Medical revenues rose by 10 percent over 2006 to \$3.42 billion. Strong sales in Pharmaceutical Systems significantly led revenue growth. Sales of safety-engineered products grew 30 percent internationally and 6 percent in the United States.

BD Diagnostics revenues rose by 11 percent over 2006 to \$1.9 billion. This growth includes \$88 million of revenues from TriPath, which was acquired at the end of the first quarter of fiscal 2007. Sales of safety-engineered products rose by 25 percent internationally and 9 percent in the United States, due in large part to *BD Vacutainer* Push Button Blood Collection Set conversion activity.

BD Biosciences revenues rose by 13 percent over 2006 to \$1.03 billion. Continued strong sales of flow cytometry and bioimaging instruments, flow cytometry reagents and bionutrients from our Advanced Bioprocessing platform contributed to growth.

Growth through innovation

BD is innovating for impact. Because continual innovation requires ongoing investments, we are investing for the future primarily through increasing the pace of R&D spending and, as appropriate, through strategic investments, such as GeneOhm and TriPath. In 2007, R&D spending increased by a rate of 19 percent (7 percent from TriPath), as revenue growth and margin expansion enabled us to invest in new growth initiatives. We also made good progress implementing our product development system, an integral element of BD's innovation culture.

Corporate social responsibility

Around the world, BD and our associates are making a difference in human health, saving and improving lives of people in all corners of the globe through our charitable initiatives and partnerships. In 2007, we strengthened our product donation program by providing product in advance of disasters, better enabling our partners to respond quickly, as during airlifts to aid the victims of the Peru earthquake. Additionally, BD launched support for Heart to Heart International's Ready Relief™ Box program, which provides international medical teams with essential medicines, instruments and supplies that treat 1,000 patients per box.

BD also announced two actions to help address HIV/AIDS and tuberculosis (TB), health pandemics causing high mortality in developing countries. In a major commitment to strengthen laboratory practices in African countries severely affected by HIV/AIDS and TB, we entered into an agreement with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), which is the largest international public health initiative directed at a single disease that any nation has ever undertaken. We also

*See reconciliations on page 64.

expanded our relationship with the Foundation for Innovative New Diagnostics (FIND) to include a new charitable component. Through cash and product donations, BD is supporting FIND's TB program to help strengthen laboratory services in developing countries, critical in combating the rapid increase in multi-drug-resistant TB.

The special insert following this letter, "Bringing our corporate purpose to life," highlights several unique programs and activities around the world that demonstrate BD's commitment to volunteerism, community, safety and the environment.

BD's standing in the corporate community, and in the medical technology industry, continues to be enhanced. In 2007, BD was again selected as a component of the Dow Jones Sustainability World Index, widely considered to be the premier socially responsible investing index, placing us in the top 10 percent of healthcare sector companies assessed in terms of sustainability leadership. BD was also again named one of "America's Most Admired Companies®" by *FORTUNE* magazine, ranking first in our industry in social responsibility, quality of management, financial soundness and quality of products and services.

Additionally, *Ethisphere Magazine* named BD to its inaugural list of the "World's Most Ethical Companies." We are proud of this recognition, but we are mindful that we must continue to keep and earn this honor every day. Ethical and compliant behavior is part of everyone's job at BD. To foster an environment encouraging that behavior, senior management is actively involved in setting the appropriate tone at the top and ensuring that the tone resonates throughout the organization. BD's Core Values, including "We do what is

right," are embedded in our culture, and our global training program, which reaches every associate, drives ethics and compliance throughout the Company.

Great place to work

Our corporate learning initiative, BD University (BDU), is strengthening our organizational and individual capabilities. We have integrated BDU with other key levers for leadership development, including talent acquisition and HR planning, to create a robust engine for the identification and development of current and future leaders. In 2007, ASTD, the world's largest professional society focusing on workplace learning and performance, recognized BD with a "BEST" Award and ranked BD in the top five submissions from over 100 companies from eight countries.

Our diversity and inclusion initiative remains a global business imperative. We are committed to fostering a culture that values and respects each individual, offering diversity awareness workshops worldwide and integrating related concepts and principles into our human resource systems. BD associates at all levels are working toward a culture that fully embraces and embodies diversity and inclusion.

A growing number of retirement-eligible associates, decreasing birthrates and increasing job growth are driving heightened competition for talent worldwide. To effectively compete, BD must implement worldwide and regional talent sourcing, development, engagement and retention strategies in new ways. Leadership involvement in these important talent management practices will elevate our organizational performance.

Office of the Chief Executive Officer

Left to right: William A. Kozy, Executive Vice President; A. John Hanson, Executive Vice President; Edward J. Ludwig, Chairman, President and Chief Executive Officer; John R. Considine, Senior Executive Vice President and Chief Financial Officer; Vincent A. Forlenza, Executive Vice President; and Gary M. Cohen, Executive Vice President.



Key management developments

It is my pleasure this year to welcome Scott P. Bruder, M.D., Ph.D., as Senior Vice President and Chief Technology Officer. Dr. Bruder, who joined us from Johnson & Johnson, is responsible for providing R&D, strategy and development leadership as BD focuses on advancing innovation in medical devices, diagnostics and biosciences. He brings a wealth of scientific and industry experience that will help us chart BD's course for the future.

Key Board developments

We are fortunate to have a broadly talented, dynamic and committed Board of Directors to complement our strong executive team. This year, we added two prominent individuals to the Board. Marshall O. Larsen, Chairman, President and Chief Executive Officer of Goodrich Corporation, is a well-regarded and distinguished business leader with a proven 30-year track record from a large, world-class manufacturing company. Cathy E. Minehan, retired President and Chief Executive Officer of the Federal Reserve Bank of Boston, offers the Board expertise in financial and economic policymaking gained during her notable career as one of the nation's central bankers.

We would also like to express our deep appreciation to James E. Perrella for his many contributions to our success

during his 12 years of service to the Board. Mr. Perrella will retire from the Board after our Annual Meeting of Shareholders in January 2008. He brought the highly valued perspective and insights of a chief executive officer of a large, public industrial company. We thank him for his efforts and wish him the very best for the future.

Closing reflections

Our solid performance in 2007 provides us with a strong base upon which to grow even further in the future. We will pursue our strategic course and drive innovation by designing and introducing products that have real value for healthcare workers, patients and researchers. We are developing strong leaders who will have the necessary skills and capabilities to ensure our future success. We thank you, our shareholders, for your ongoing confidence and support, and we thank our customers, partners and dedicated associates for their collective efforts toward *"Helping all people live healthy lives."*



Edward J. Ludwig
Chairman, President and Chief Executive Officer

Development Committee

Left to right: Scott P. Bruder, M.D., Ph.D., Senior Vice President and Chief Technology Officer; David T. Durack, M.D., Senior Vice President, Corporate Medical Affairs; John R. Considine, Senior Executive Vice President and Chief Financial Officer; Donna M. Boles, Senior Vice President, Human Resources; William A. Kozy, Executive Vice President; Edward J. Ludwig, Chairman, President and Chief Executive Officer; Vincent A. Forlenza, Executive Vice President; Gary M. Cohen, Executive Vice President; Patricia B. Shrader, Senior Vice President, Corporate Regulatory and External Affairs; Jeffrey S. Sherman, Senior Vice President and General Counsel; and A. John Hanson, Executive Vice President.





Bringing our corporate purpose to life

“Helping all people live healthy lives” is BD’s corporate purpose and the inspiration behind our global enterprise. It is also a call to action that resounds with BD associates the world over. By giving our time, our talent and our resources, we not only improve many lives, but also save many more. The following stories highlight just a few examples of how we are striving to reduce the burden of disease, raise health standards, protect the environment and ensure safe workplace conditions.





Volunteerism

In Ghana, BD volunteers build essential healthcare infrastructure

In a joint effort with Direct Relief International, a nonprofit humanitarian medical aid organization, 12 BD associates from around the world devoted three weeks to upgrading two healthcare clinics in Ghana. The April 2007 trip marked the third consecutive year that BD associate volunteers worked to strengthen healthcare infrastructure in sub-Saharan Africa by participating in the Company's Volunteer Service Trip Program.

The BD volunteers worked side-by-side with clinic staff and Direct Relief partners to train healthcare providers, construct a new health facility, improve laboratory capabilities and incorporate clean water solutions at the Maranatha Maternity Clinic and the Motoka Clinic.

Located in Kumasi, Ghana's second largest city, the Maranatha Maternity Clinic serves approximately 250 patients each month, about 40 percent of whom are unable to pay for medical treatment.

The BD team also helped construct a new satellite clinic outside Kumasi in the Bonkwaso village on what had been an overgrown field. The volunteers then outfitted it with medical equipment and an electrical generator—the first electricity in Bonkwaso. With support from BD, four local students studied in Kumasi and returned to serve as the clinic's staff.



Speaking about the efforts of BD volunteers, Agatha Amoateng-Boahen, head nurse at the clinic, said, “The BD team had such a great and positive impact. Our laboratory has taken a new shape and thus is helping to provide quality services to our patients. Above all, the team on individual levels sacrificed a lot to help patients with chronic diseases.”

Established in 1996, the rural Motoka Clinic is the only healthcare resource serving a district of nearly 100,000 people. The services offered by the clinic, which is located on Lake Volta, are complemented by outreach visits to villages accessible only by boat. Reflecting on the effort, BD volunteer Paul Soskey said, “The clinic now has the best equipped lab in the whole West Krachi District of the Volta region.” One incident brought home to Soskey the significance of what the team had done: “We installed a blood bank refrigerator with a complete battery-based backup power source and a sample incubator. While we were there, an anemic six-year-old boy was transfused with blood from the blood bank, giving him a chance to recover overnight.”

This journey to Ghana follows similar initiatives in 2005 and 2006, when BD associates volunteered in Zambia to help strengthen the country’s capacity to diagnose and treat HIV/AIDS.



Photos courtesy of the International Council of Nurses

Philanthropy

BD supports initiative to provide care for the caregivers in Africa

Healthcare systems in sub-Saharan Africa are strained by a dramatic shortage of human resources, largely due to the HIV/AIDS pandemic, migration and poor working conditions. Healthcare workers and clinicians, particularly those on the front lines, are often over-stressed and undervalued, and frequently at risk for infection from occupational exposures.

To address the situation, BD and the International Council of Nurses (ICN) are establishing Wellness Centers in four countries hardest hit by the HIV/AIDS pandemic and healthcare worker shortages. These Centers will provide comprehensive health services for thousands of healthcare workers and their families. The goal is to sustain a healthy and productive healthcare work force, leading to a stronger regional healthcare delivery system.

The Centers offer testing, counseling and treatment for HIV/AIDS and tuberculosis (TB); prenatal services; stress management; screening for chronic conditions; and training for continuous professional development, including prevention of occupational exposures. BD is providing \$120,000 in cash support to help fund the Wellness Centers, as well as training in safe injection and phlebotomy practices valued at more than \$200,000.

The first Wellness Center in Swaziland was hailed as a model of good practice by the World Health Organization and Physicians for Human Rights. ICN and its member national nurses associations are opening additional Wellness Centers with BD support in Lesotho, Zambia and Malawi.



Photos courtesy of Project HOPE

Community involvement

BD extends support for diabetes training and education program in China

BD extended its partnership for an additional two years with Project HOPE, a global nonprofit organization whose name stands for "Health Opportunities for People Everywhere," to address the rise of diabetes in China. The Company's support for the China Diabetes Education Program (CDEP), which provides comprehensive diabetes training to local healthcare providers, will allow the program to further increase public awareness about diabetes and the importance of better diabetes care. It will also provide CDEP the opportunity to collaborate with the Chinese government to improve community care.

Approximately 39 million Chinese citizens are estimated to have diabetes, a figure that could rise to as many as 100 million by 2010. Due to a lack of patient education and training in China, however, many people with diabetes are unaware of the healthcare and lifestyle measures that can alleviate and postpone complications.

Since 1998, CDEP trainers from more than 800 local hospitals and community care centers have trained nearly 37,000 physicians and approximately 170,000 nurses, healthcare workers and patients with diabetes.

The CDEP program establishes diabetes education and training centers; promulgates a state-of-the-art training model; and develops education and training materials. The program has won strong support from China's Ministry of Health.



Environmental responsibility

Utah facility committing to renewable energy sources

BD's facility in Sandy, Utah, is reducing its dependence on fossil fuels by committing to one of the largest "Blue Sky" renewable energy purchases to date in the state. Through Rocky Mountain Power's Blue Sky program, the Sandy facility agreed to buy 2,944 100-kilowatt-hour blocks of renewable energy monthly, all generated by renewable sources such as wind, solar, geothermal, biomass, wave and low-impact hydro sources, instead of coal, fuel oil and natural gas.

"We want to send a message to our associates, customers and community that we are committed to sustainable growth and the long-term health of the environment," says Travis Anderton, the facility's safety and environmental manager.

Over the span of a year, BD's Blue Sky commitment is estimated to offset 3,533 tons of carbon dioxide emissions, providing annual environmental benefits equivalent to a 7.5-million-mile reduction in driving or planting approximately 1,388 acres of trees.

In 2007, 10 percent of the facility's electricity use will be matched to renewable energy purchases. The goal is to support renewable energy generation equal to 25 percent of the plant's electricity use by 2010.



Occupational safety

Grassroots safety efforts earn honors for BD facilities

Ensuring workplace safety is of paramount concern for BD facilities around the globe. It is the responsibility of every associate, and many solutions begin with shop floor associates teaming to address safety issues with simple, innovative and cost-effective solutions. These grassroots activities are earning recognition in the occupational safety community.

BD's facility in Yishun, Singapore—which has experienced just one lost-time incident since 2003—received two Occupational Safety and Health (OSH) Awards from the country's Ministry of Manpower in 2007. The facility won a top award in the Innovation for OSH award category and its third consecutive gold award in the Annual Safety and Health Performance category. Both carry stringent criteria and are recognized as major accomplishments in the Singapore business community.


In 2007, the Nebraska Safety Council honored two BD facilities in Nebraska for their commitment to workplace safety. The BD Medical-Pharmaceutical Systems facility in Columbus earned the Council's Peak Performance Award for its low safety incident rate in 2006. The BD Diagnostics facility in Broken Bow received a Star Award for its excellent safety performance, training programs and initiatives to eliminate common workplace injuries.



Collaboration

Humanitarian partners mark milestone anniversaries

Through longstanding relationships with nonprofit partners, BD annually donates millions of dollars in financial support and products for emergency relief and healthcare services. We applaud five of our partners as they commemorate landmark anniversaries in 2007 and 2008.



...75 years




...60 years



...50 years



...25 years



...15 years

Addressing global healthcare needs

A young adult suffering from HIV/AIDS...a laboratory specialist seeking a way to diagnose cervical cancer earlier...a medical director looking to eliminate the risk of potentially deadly staph infections...a biopharmaceutical company needing a reliable partner to support its entry into an innovative new class of biologic therapies. For BD, these disparate needs are equally important – and equally compelling. They are the drivers in our relentless search for solutions to some of today's most pressing healthcare challenges.

At BD, everything we do starts with the healthcare needs of people from all walks of life, all around the world. Our response reflects a commitment to improve healthcare through innovations in technology and product development, excellence in manufacturing and operations, collaborations with organizations that share our values, and global customer service and support. Woven into the fabric of all that we do is the passion that BD associates bring to their work – a passion inspired by the knowledge that they can make a difference “*Helping all people live healthy lives.*”

Reducing the spread of infection

One key to reversing the rising incidence of healthcare-associated infections (HAIs) is active surveillance of patients entering healthcare facilities, which requires a diagnostic test with the ability to screen broad patient populations for the presence of dangerous organisms and rapidly deliver reliable, actionable results. To respond to this need, BD offers molecular diagnostic tests for swift, accurate detection of MRSA (methicillin-resistant *Staphylococcus aureus*). This technology, which produces results in less than two hours, offers BD customers a valuable tool to help prevent the spread of these potentially deadly and costly HAIs. The customer base for the *BD GeneOhm* MRSA assay has grown to more than 250 hospitals in the U.S., Canada, Europe and Asia-Pacific. BD plans to expand its menu of HAI assays and anticipates launching a new automated diagnostic platform in 2008.

“UCLH has cut MRSA infections by more than half, making us a leader in the U.K.’s nationwide effort to reach the same goal in 2008. On average, 5 percent of surgical patients admitted here carry MRSA. Rapid molecular testing enables us to detect when MRSA is present and respond with appropriate treatment to prevent both the spread within the hospital and later surgical infection.”

— Dr. Peter Wilson
University College London Hospitals

BD is collaborating with medical professional societies to build awareness and educate healthcare providers about the patient and economic benefits of using active surveillance to prevent the spread of HAIs. Many of the world’s leading healthcare institutions and networks have taken note. The U.S. Veterans Health Administration now recommends rapid molecular testing for all incoming patients at its 153 hospitals, and both the U.K. and Germany have initiated national MRSA reduction programs.

In addition to helping healthcare facilities prevent the spread of HAIs, BD has been a pioneer and world leader since 1988 in developing safety-engineered needle devices designed to protect healthcare workers and patients from exposures to bloodborne pathogens. The Company prides itself on its ability to design products that reflect an intimate knowledge of clinical processes and a deep understanding of customers’ needs. For example, the safety-engineered *BD Nexiva* Closed IV Catheter System with *BD Q-Syte* Luer Access Split-Septum Device is designed to help simplify the intravenous therapy process and reduce the potential for bloodstream infections that can be introduced through IV therapy.

While the U.S. healthcare system has largely transitioned to safety-engineered syringes, catheters and blood collection devices, the need to enhance healthcare worker safety still remains outside North America, as adoption of safety-engineered technologies is currently lower in Europe and other geographic regions. BD is well positioned to help address this need with its expertise and innovative product portfolio, including products tailored to the requirements of specific regional markets.

The innovative *BD Nexiva* Closed

IV Catheter System, which includes the *BD Q-Syte* Luer Access Split-Septum Device,

is designed to address catheter-related bloodstream infections, reduce

blood exposure to the clinician and the patient, and provide protection against accidental needlestick injuries.





Infectious microorganisms lurk everywhere, even in the places people go to preserve or recover their health, such as hospitals, clinics and other healthcare facilities. Left undetected and uncontrolled, harmful bacteria – including drug-resistant “superbugs” such as MRSA (methicillin-resistant *Staphylococcus aureus*) – can be passed from patient to caregiver to another patient in an insidious chain. When patients become infected, particularly those with weakened resistance and immunity, the consequences can be deadly. In fact, new data from the Centers for Disease Control and Prevention indicate that more than 94,000 Americans were infected with MRSA in 2005, and nearly 19,000 died. Overall, an estimated six million healthcare-associated infections (HAIs) occur each year in the U.S., Europe and Japan, killing approximately 99,000 people in the U.S. alone. HAIs not only take a human toll, they also cost an average of \$27,000 per infected patient to treat in the U.S.

Delivering results in less than two hours, the *BD GeneOhm* MRSA assay is a rapid, qualitative *in vitro* diagnostic test for the direct detection of nasal colonization by MRSA to aid in the prevention and control of healthcare-associated infections.



Improving global health

In the developing world, BD's multi-dimensional approach to tackling HIV/AIDS positions the Company to make a significant impact in the fight against this disease and its deadly companion, tuberculosis (TB). Recognizing that no single technology or company will defeat these diseases, BD has mobilized on many fronts—calling on its leading technology, expertise, experience, global presence and strong relationships with governmental and nongovernmental organizations to address problems that limit access to healthcare services in the developing world.

BD continues to invest in products and technologies specifically designed to meet the needs of developing countries, emphasizing affordability. CD4 testing, which measures the deterioration of the immune systems of people living with

HIV, is used to determine the need for antiretroviral (ARV) therapy and to monitor its progress. Laboratories in more than 120 developing countries are currently using *BD FACSCount* and *BD FACSCalibur* flow cytometers for CD4 monitoring. To improve the effectiveness of these technologies, BD has trained more than 3,400 laboratory workers in 57 countries through BD Good Laboratory Practice workshops.

In a major commitment to strengthen laboratory practices in African countries severely affected by HIV/AIDS and TB, BD entered into an agreement in 2007 with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), which is the largest international public health initiative directed at a single disease that any nation has ever undertaken. Under the agreement, BD and PEPFAR have each committed up to \$9 million in in-kind associate support and financial resources toward this five-year public-private partnership to bolster training and improve diagnostic testing critical to managing the care of HIV/AIDS patients.

In the face of increasing drug-resistant forms of TB, rapid culture and drug susceptibility testing are more important than ever. However, TB culture testing is widely underutilized. In addition, the most commonly used method takes up to six weeks for results. This delay could be deadly for infected people in the developing world. The *BD BACTEC MGIT System* dramatically shortens mycobacterial culture recovery time, typically to 10-14 days.

The *BD BACTEC MGIT 960 System* is the world's only automated system for high-volume mycobacteria growth, detection and susceptibility testing for TB—providing faster results that help improve patient care and lower healthcare costs.



“The world now recognizes the magnitude of the crisis surrounding HIV/AIDS, TB and malaria in the developing world. However, effectively combating these three deadly diseases requires much more than providing access to drug therapies. Governments, philanthropic organizations and private industry must work together to bolster healthcare infrastructure, such as improving laboratory capabilities and training of both lab technicians and clinical personnel in order to support and complement new treatment programs.”

— Thomas Quinn, M.D.
Professor of Medicine
Director, Johns Hopkins Center for Global Health



An infant in Lesotho, a mother in Thailand and a teenager in Hungary are just a few of the human faces of the global HIV/AIDS pandemic that afflicted an estimated 33 million people in 2007. Of those suffering, the vast majority live in developing countries. Most patients would benefit from antiretroviral (ARV) therapy, but only about 20 percent actually receive it. The problem largely stems from a lack of basic healthcare infrastructure, including substandard facilities and severe shortages of trained clinicians and laboratory workers. Compounding the problem is tuberculosis (TB), a disease once considered controlled that is now re-emerging to prey upon HIV/AIDS patients with weakened immune systems. TB is also evolving into even deadlier drug-resistant strains that must be identified and treated to prevent a global outbreak.

The *BD FACSCount* System is the workhorse flow cytometer in the developing world for CD4 testing, used to monitor immune status and disease progression in HIV-infected individuals. The system is supported by the use of the *BD Vacutainer* CD4 Stabilization Tube, which is currently available only in Africa and designed to ensure specimen integrity during sample transport and storage.



Improving the detection and management of cancer

BD is improving the clinical management of cancer—and establishing a source of future business growth.

BD expanded its presence in cancer diagnostics through the 2006 acquisition of TriPath Imaging, which gave the Company innovative oncology management tools that span cancer screening, diagnosis, prognosis and therapy monitoring. The TriPath platform provides BD with an effective tool for cervical cancer screening. In the U.S., approximately 90 percent of Pap smears are collected using liquid-based cytology. This approach is preferred because it produces a better picture of cellular-level conditions.

The *BD SurePath* Liquid-Based Pap Test uses collection devices that ensure all gathered cells are sent to the laboratory for analysis, which can mean the difference between finding

disease and missing it. Once at the lab, the *BD SurePath* sample creates a very clear slide that is easy to screen for abnormal cells. BD is working with physician thought leaders and government officials in other markets to encourage adoption of liquid-based cytology testing methods. In addition, BD currently has clinical trials underway to evaluate a product utilizing molecular markers aimed at improving the reliability of detecting cervical cancer.

Over the longer term, BD is pursuing serum-based screening and monitoring assays for ovarian cancer based upon the detection of proprietary biomarker panels. The Company plans to provide new tests that will help detect and improve the management of ovarian cancer. At present, ovarian cancer is rarely detected early and most often results in death within five years. BD is also researching the use of proprietary molecular biomarkers and reagents to predict a patient's risk of breast cancer recurrence and to help select treatment for patients in the early stages of disease.

Flow cytometry—a field in which BD is a recognized leader—is considered an effective technology for providing information used in the diagnosis and monitoring of “liquid tumors,” leukemia and lymphoma. BD offers clinical laboratories distinct performance advantages with instruments such as the *BD FACSCanto II* System, which increases the number of parameters that can be measured simultaneously to give clinicians confidence in their diagnosis and treatment decisions.

“Ovarian cancer is a very challenging disease to manage. Its prevalence is actually low, but its mortality rate is very high. However, if we had a routine test available to detect ovarian cancer in its early stages, it could provide physicians with a valuable tool to identify women afflicted by the disease, while it is still localized and surgically removable.”

— Andrew Berchuck, M.D.
Director, Division of Gynecologic Oncology
Duke University Medical Center


The *BD FACSCanto II* System offers flexible applications that enable clinical laboratories to develop assays that aid in the diagnosis and monitoring of leukemia and lymphoma.






An estimated 7.6 million people around the world died of cancer in 2005. Early detection and effective disease management are the keys to reducing cancer mortality rates and improving the quality of life for patients. This is particularly evident in the cases of cervical and ovarian cancers, which claim the lives of thousands of women each year. While most cervical cancers are caused by the human papilloma virus (HPV), a positive HPV test does not necessarily indicate cancer. The conventional Pap smear often does not provide conclusive information. As a result, doctors frequently order unnecessary biopsies. Most ovarian cancers are found only after symptoms appear – too late for effective treatment – because no reliable early screening test currently exists.

The *BD SurePath* Liquid-Based Pap Test, collection method and cell enrichment process offer laboratory professionals and clinicians a significant improvement over conventional Pap technologies. Together, they provide better visualization of clinically relevant cells that may indicate the presence of cervical cancer.



Conventional slide
Bloody specimen



BD SurePath Test
Same sample after
cell enrichment

Enhancing pharmaceutical therapies

Innovation and a commitment to advancing research help BD remain at the leading edge of drug discovery, production and delivery.

BD's contributions to drug discovery can be traced to the very first commercial flow cytometer, which the Company brought to market in 1973. Today, major pharmaceutical companies as well as medical and academic research centers the world over use BD flow cytometry platforms—including cell sorters, analyzers, software and reagents—to identify cells and better understand their functions and the effects new drug candidates have on them.

The Company continually innovates to keep BD flow cytometers at the center of drug and vaccine research and development. Researchers use *BD Phosflow* technology to analyze cell signaling

pathways to understand how experimental drugs might impact these pathways and inhibit the spread of disease. *BD Cytometric Bead Arrays* allow researchers to analyze multiple markers at the same time, increasing efficiency and delivering more results from smaller samples. BD also helps pharmaceutical and biotechnology customers and partners develop new medicines tailored to specific patient sub-populations by collaborating on the development of biomarkers and companion diagnostic assays.

Drug production is undergoing a major change, as generations of chemically derived small molecule drugs are joined by newer, biologically derived large molecule therapies. In response, BD established a new product platform, Advanced Bio-processing, to enable the industry to produce higher volumes of biopharmaceuticals efficiently and safely. With its high-quality, consistent cell culture media supplements already used in 19 drugs and vaccines, BD is expanding its product scope and adding production capacity.

When the most demanding pharmaceutical and biotechnology companies look for better ways to deliver injectable drugs and vaccines, they turn to BD—the world's leading provider of prefillable drug delivery systems. To meet the growing demand for *BD Hypak SCF*—sterile, clean, ready-to-fill—Glass Prefillable Syringes, BD is making significant investments in high-volume manufacturing, while also enhancing quality and providing customized systems that respond to the specific requirements of each drug or vaccine. BD also continues to invest in advanced injectable drug delivery systems by developing novel prefillable “Micro-Delivery” devices and self-injection devices for chronic therapies.

BD Hypak SCF Glass Prefillable Syringes are the worldwide standard for glass prefillable drug delivery systems, combining high-quality design with accurate dosing and easy customization options.



“In the pharmaceutical industry, the need to improve the efficiency of drug discovery and development has led to biomarker analysis at all stages of the process—discovery, toxicology, clinical trials. Using flow cytometry, data on cellular functioning in response to new therapies can be evaluated in a high throughput, reproducible and specific manner. Ultimately, this could lead to safer and more effective therapies.”

— Virginia M. Litwin, Ph.D.
Laboratory Director
MDS Pharma Services



The journey of a new drug from the research laboratory through clinical trials to regulatory approval is long, costly and fraught with obstacles that could preclude the therapy from ever reaching patients. In the U.S., pharmaceutical companies can spend more than 10 years and \$800 million to develop a new therapy and obtain FDA approval. A real need exists to speed this process and reduce the cost of developing new therapies. Promising new therapies and vaccines are emerging from the industry's increasing shift to biopharmaceuticals—but production capacity is still limited. Additionally, companies manufacturing these biotechnology drugs are seeking advanced injection-based delivery systems to increase the efficacy of their therapies.


The *BD LSR II* Flow Cytometer is an extremely flexible, powerful benchtop analyzer. Its innovative optics and digital electronics yield detailed insights into how cells work that ultimately help researchers develop better and safer drugs.



Enterprise Profile

BD Medical is among the world's leading suppliers of medical devices.

BD built the first-ever manufacturing facility in the U.S. to produce syringes and needles in 1906 and has been the leading innovator in injection- and infusion-based drug delivery ever since.



Principal product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/ scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; sharps disposal containers; and home healthcare products such as ACE brand elastic bandages.

BD Medical's business strategy is focused on effectively addressing four global health needs:


Preventing the spread of infection...with an extensive line of safety-engineered devices to reduce the risk of sharps injuries to healthcare workers around the world—a field in which BD is a global leader. We provide innovative IV flush syringes and closed IV catheter systems designed to enhance patient safety by reducing the potential for medical errors and device contamination while promoting healthcare worker safety. We also offer low-cost, auto-disabling injection devices for immunization and parenteral therapies, intended to prevent disease spread associated with syringe reuse in developing countries.

Enhancing diabetes treatment...by offering the world's leading devices for insulin injection and award-winning educational programs to help people with diabetes help themselves. BD developed the first syringe dedicated

to insulin delivery in 1924 and has made continuous advances ever since, developing a deep understanding of the needs, preferences and lifestyles of those who self-inject insulin. Today's insulin injection needles are tiny and virtually pain-free. Insulin injection offers precise dose control to help patients achieve tighter control of their blood glucose levels, which helps reduce the risk of complications from diabetes. We are increasing insulin pen needle manufacturing capacity to meet the rising global prevalence of diabetes, and we are expanding application of these products for both insulin and non-insulin diabetes treatments.

Advancing drug delivery...as the category leader in prefillable devices, BD works with more than 200 pharmaceutical companies. Injectable drugs sold in glass and plastic prefilled syringe formats reduce the potential for medication error and contamination while providing drug companies with a means to differentiate their offerings. Two areas of innovation include an advanced "Micro-Delivery" platform for injection of vaccines that may offer important therapeutic advantages over conventional injection methods, and self-injection devices to ease administration of injectable drugs by patients in a home setting.

Improving ophthalmic surgery outcomes...through new technologies that enhance blade sharpness while protecting ophthalmic surgeons and their staffs from occupational injury. We offer single-use knives, surgical instruments and procedure packs as well as other ophthalmic accessories.



Tiny and virtually pain free, BD Pen Needles are universally compatible with all leading diabetes pens and dosers, including those made by Eli Lilly and Company, such as the KwikPen™ prefilled with the Humalog® brand of insulins, as well as Lantus® and Apidra® SoloSTAR® made by sanofi-aventis.




The *BD Uniject* Prefillable Injection System is a single-use system, preventing needle reuse and eliminating the need for filling syringes from vials. Its innovative design allows for fast and easy injections, while the compact size allows easy transport, storage and disposal.



The *BD Venflon Pro* Safety Catheter, launched in 2007, meets the unique needs of European clinicians by providing both enhanced needlestick safety and reduced blood exposure.

Enterprise Profile

BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostic specimens and instruments for quick, accurate analysis across a broad range of infectious diseases, including the growing problem of healthcare-associated infections (HAIs). The segment is composed of two operating units: **Preamanalytical Systems**, a world leader in sample collection, and **Diagnostic Systems**, a leader in microbiology testing products and molecular assays.



Principal products and services include integrated systems for specimen collection; an extensive line of safety-engineered blood collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; and rapid diagnostic assays.

BD Diagnostics focuses on improving health outcomes for patients and providing laboratories with solutions that elevate quality, reduce costs, guide medical decisions and enhance the productivity of laboratory systems. Developing products that effectively integrate laboratory work processes, diagnostic testing procedures and information management is central to our business.

Preamanalytical Systems focuses on specimen collection and accelerating growth through continued emphasis on safety, where innovation has led to second- and third-generation safety-engineered products offering greater protection and improved functionality. The conversion of emerging markets to evacuated tubes is also a priority.

Looking ahead, we are concentrating on new opportunities driven by emerging technologies—including molecular diagnostics and proteomics—and look to build our sample collection, stabilization and processing capabilities in these areas.

Diagnostic Systems continues to be a leader in microbiology and infectious disease diagnostics. Our focus on growth

media—for both the clinical and industrial market segments—is the foundation of strong customer relationships and an entry point for instrument platforms. Our *BD BACTEC* and *BD Phoenix* Systems are important tools for microbiologists seeking clinically relevant answers for patients with life-threatening infections. The information these instruments provide is transferred to the *BD Epicenter* Microbiology Data Management System, which can alert physicians, infection control personnel and pharmacists who may need to take immediate action.

BD GeneOhm assays offer customers a menu of molecular diagnostics to rapidly identify some microorganisms that cause HAIs, such as the deadly strains of MRSA (methicillin-resistant *Staphylococcus aureus*). BD's molecular diagnostics instruments, the *BD ProbeTec* and *BD Viper* Systems, used with our DNA-amplified assays, also help hundreds of laboratories worldwide detect sexually transmitted diseases. They provide reliable information that physicians need to make early diagnoses and use state-of-the-art automation to boost laboratory efficiency.

Our TriPath platform develops, manufactures and markets innovative solutions to improve the clinical management of cancer.

Looking forward, we plan to build on our unique instrument product portfolio and engineering capabilities to provide a range of systems to rapidly diagnose infectious diseases and detect cancer earlier.



The *BD Vacutainer* Push Button Blood Collection Set is BD's next-generation

safety-engineered wingset offering healthcare workers in-vein activation and split-second protection at the push of a button.



The *BD Phoenix* Automated Microbiology


System consistently identifies more than 300 clinically relevant bacteria and assesses the pathogens' resistance and susceptibility to antibiotic treatments in less than 16 hours.



The *BD Viper* System combines state-of-the-art molecular testing and robotic automation to help clinical laboratories detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in patient samples earlier and more accurately, which can lead to more timely and effective treatment.

Enterprise Profile

BD Biosciences is one of the world's leading businesses bringing innovative tools to life scientists, clinical researchers and clinicians. Our customers are involved in basic research, drug and vaccine discovery and development, biopharmaceutical production, clinical trials, diagnostic testing and disease management.



Principal product lines include fluorescence-activated cell sorters and analyzers; cell imaging systems; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; tools to aid in drug discovery and growth of living cells and tissue; cell culture media supplements for biopharmaceutical manufacturing; and diagnostic assays. Our diverse global customer base includes academic and government institutions, pharmaceutical and biotechnology companies, and both commercial reference labs and hospitals in the clinical laboratory segment.

Cell analysis is the focus of our Immunocytometry Systems and Pharmingen units, which together have experienced solid growth driven by proven instrument platforms, improved software solutions and reagents. Throughout the world, researchers rely on our state-of-the-art technologies, products and leading expertise to study cells to better understand disease, speed the discovery and development of novel therapeutics, and improve diagnosis and disease management. Recent launches of several flow cytometry platforms and associated sample preparation and automation systems have helped us lead the way in all major customer segments.

Research instruments, including the *BD FACSAria* and *BD LSR II* flow cytometers, and our broad array of monoclonal-based research reagents, are the tools of choice in cellular

research laboratories around the world. New bioimaging instruments enable researchers to better understand biological processes through real-time imaging of live cell processes.

Our **clinical flow cytometry platforms**, such as the *BD FACSCount* and *BD FACSCalibur* Systems, are considered the "gold standard" for CD4 testing, which is utilized worldwide to monitor HIV/AIDS therapy. Flow cytometry is also widely used for typing leukemia and lymphoma. We plan to develop new platforms and assays in response to unmet and growing needs in the clinical segment.

BD Biosciences also focuses on serving researchers from pharmaceutical and biotechnology companies. Our growing line of drug metabolism assays from the Discovery Labware unit help screen out nonviable drug candidates early, increasing the ultimate likelihood of clinical trial success. In addition, our broad array of laboratory products for tissue culture and fluid handling are utilized in research laboratories globally.

Finally, BD Biosciences collaborates with leading biotechnology companies to enhance the production of their biopharmaceuticals. Our Advanced Bioprocessing platform provides unique cell culture media supplements to optimize production yield for vaccines and therapeutic proteins.



BD's Advanced Bioprocessing cell culture media supplements are increasingly being adopted as critical components in the production of many lifesaving biological medicines on the global market.



The novel product design of the *BD Falcon* 50 ml Conical Tube with Flip-Top Cap saves time and effort in applications requiring multiple aliquoting, storage and pouring from the same tube, while maintaining the same superior quality and performance of BD's standard screw-cap closure.




The *BD Pathway* 855 System offers the ultimate in flexibility for high-content imaging of live and fixed cells. Its powerful features enable the system to rapidly record high-resolution fluorescent images from multiwell plates and slides.


Financial Table of Contents

	Page
Ten-Year Summary of Selected Financial Data	18
Financial Review	20
Reports of Management	33
Reports of Independent Registered Public Accounting Firm	34
Consolidated Statements of Income	36
Consolidated Statements of Comprehensive Income	37
Consolidated Balance Sheets	38
Consolidated Statements of Cash Flows	39
Notes to Consolidated Financial Statements	40
Quarterly Data (unaudited)	62


U.S. Revenues
(Millions of Dollars)




Non-U.S. Revenues
(Millions of Dollars)




Net Income
(Millions of Dollars)




Return on Invested Capital
(Percent)



Earnings Per Share—Diluted
(Dollars)



Dividends Per Common Share
(Dollars)



Ten-Year Summary of Selected Financial Data

Years Ended September 30

Dollars in millions, except per share amounts

	2007	2006	2005	2004
Operations				
Revenues	\$6,359.7	\$5,738.0	\$5,340.8	\$4,893.9
Research and Development Expense	360.1	301.9	267.7	230.8
Operating Income	1,203.2	1,141.4	1,063.8	878.2
Interest Expense, Net	.2	6.8	19.3	29.6
Income From Continuing Operations				
Before Income Taxes	1,203.9	1,125.9	1,037.5	843.8
Income Tax Provision	347.8	310.8	325.0	204.9
Net Income	890.0	752.3	722.3	467.4
Basic Earnings per Share	3.63	3.04	2.87	1.85
Diluted Earnings per Share	3.49	2.93	2.77	1.77
Dividends per Common Share	.98	.86	.72	.60
Financial Position				
Current Assets	\$3,130.6	\$3,185.3	\$2,975.3	\$2,641.3
Current Liabilities	1,478.8	1,576.3	1,299.4	1,050.1
Property, Plant and Equipment, Net	2,497.3	2,133.5	1,933.7	1,881.0
Total Assets	7,329.4	6,824.5	6,132.8	5,752.6
Long-Term Debt	955.7	957.0	1,060.8	1,171.5
Shareholders' Equity	4,362.0	3,836.2	3,284.0	3,067.9
Book Value per Common Share	17.89	15.63	13.26	12.30
Financial Relationships				
Gross Profit Margin	51.7%	51.3%	50.9%	50.5%
Return on Revenues ^(E)	13.5%	14.2%	13.3%	13.1%
Return on Total Assets ^{(B)(E)}	17.7%	18.4%	18.4%	15.7%
Return on Equity ^(E)	20.9%	22.9%	22.4%	21.4%
Debt to Capitalization ^{(D)(E)}	20.9%	25.8%	27.1%	28.1%
Additional Data				
Number of Employees	28,000	27,000	25,600	25,000
Number of Shareholders	8,896	9,147	9,442	9,654
Average Common and Common				
Equivalent Shares Outstanding—				
Assuming Dilution (millions)	254.8	256.6	260.7	263.3
Depreciation and Amortization	\$ 441.3	\$ 402.3	\$ 382.7	\$ 351.1
Capital Expenditures	556.4	457.1	315.8	260.5

(A) Includes cumulative effect of accounting change of \$36.8 million (\$.14 per basic and diluted share).

(B) Earnings before interest expense, taxes and cumulative effect of accounting changes as a percent of average total assets.

(C) Excludes the cumulative effect of accounting changes.

(D) Total debt as a percent of the sum of total debt, shareholders' equity and net non-current deferred income tax liabilities.

(E) Excludes discontinued operations in 1999 to 2007.

2003	2002	2001	2000	1999	1998
\$4,449.1	\$3,960.4	\$3,667.6	\$3,544.7	\$3,412.6	\$3,116.9
218.5	201.1	193.8	207.8	203.9	187.9
800.8	689.1	645.9	507.4	477.3	405.4
36.5	33.2	55.3	74.2	72.0	56.3
761.6	642.1	548.6 ^(A)	512.7	404.8	340.9
182.1	153.7	139.3	122.0	96.9	104.3
547.1	480.0	401.7 ^(A)	392.9	275.7	236.6
2.14	1.85	1.55 ^(A)	1.54	1.09	.95
2.07	1.79	1.49 ^(A)	1.49	1.04	.90
.40	.39	.38	.37	.34	.29
\$2,503.5	\$2,091.4	\$1,930.1	\$1,847.6	\$1,843.0	\$1,542.8
1,059.4	1,271.5	1,285.4	1,382.4	1,358.6	1,091.9
1,831.8	1,750.4	1,701.3	1,565.5	1,423.9	1,302.7
5,572.3	5,029.0	4,790.8	4,505.1	4,437.0	3,846.0
1,184.0	803.0	782.8	778.5	954.0	765.2
2,897.0	2,480.9	2,321.7	1,956.0	1,768.7	1,613.8
11.54	9.71	8.96	7.72	7.05	6.51
48.9%	48.3%	48.7%	48.6%	49.9%	50.6%
13.0%	12.3%	12.2% ^(C)	11.0%	9.0%	7.6%
15.2%	13.9%	13.9%	13.4%	11.6%	11.7%
21.6%	20.3%	20.7% ^(C)	21.0%	18.2%	15.8%
30.5%	32.7%	34.0%	41.7%	47.6%	41.4%
24,800	25,200	24,800	25,000	24,000	21,700
9,868	10,050	10,329	10,822	11,433	9,784
263.6	268.2	268.8	263.2	264.6	262.1
\$ 332.8	\$ 294.7	\$ 292.0	\$ 273.7	\$ 257.8	\$ 228.7
253.0	253.5	364.1	371.0	311.4	181.4

Company Overview

Becton, Dickinson and Company (“BD”) is a medical technology company engaged principally in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Our business consists of three worldwide business segments—BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). Our products are marketed in the United States and internationally through independent distribution channels, directly to end-users and by independent sales representatives. References to years throughout this discussion relate to our fiscal years, which end on September 30.

BD management operates the business consistent with the following core strategies:

- To increase revenue growth by focusing on products that deliver greater benefits to patients, healthcare workers and researchers;
- To improve operating effectiveness and balance sheet productivity; and,
- To strengthen organizational and associate capabilities in the ever-changing healthcare environment.

In assessing the outcomes of these strategies and BD’s financial condition and operating performance, management generally reviews quarterly forecast data, monthly actual results, segment sales and other similar information. We also consider trends related to certain key financial data, including gross profit margin, selling and administrative expense, investment in research and development, and cash flows.

The results of our strategies are reflected in our fiscal 2007 financial and operational performance. Worldwide revenues in 2007 of \$6.4 billion increased 11% from the prior year and reflected volume increases of approximately 8%, an estimated increase due to favorable foreign currency translation of 3%, and price increases of less than 1%. U.S. revenues increased 11% to \$3.0 billion. International revenues increased 11% to \$3.3 billion with an estimated 5 percentage points of such growth coming from the favorable impact from foreign currency. For a discussion of the financial impact of exchange rate fluctuations and the ways and extent to which we attempt to mitigate such impact, see “Financial Instrument Market Risk” below.

Consistent with our strategy to provide products that deliver greater benefits to healthcare workers, and recognizing the issues surrounding sharps-related injuries, BD has developed a wide array of safety-engineered devices that are designed to reduce the incidence of needlestick injuries and exposure to bloodborne pathogens. These products are offered through our Medical and Diagnostics segments. Sales in the United States of safety-engineered devices grew 7% to \$982 million in 2007, from \$917 million in 2006. International sales of safety-engineered devices grew 26% to \$409 million in 2007 from \$324 million in 2006. In 2008, we expect sales of safety-engineered devices to increase about 8% in the United States and 20% internationally.

Income from Continuing Operations was \$856 million, or \$3.36 per diluted share, in 2007 as compared with \$815 million, or \$3.18 per diluted share, in 2006. Comparisons of Income from Continuing Operations between 2007 and 2006 are affected by the following significant items that are reflected in our financial results:

2007

- In December 2006, we acquired TriPath Imaging, Inc. (“TriPath”). TriPath develops, manufactures, markets and sells innovative solutions to improve the clinical management of cancer, including detection, diagnosis, staging and treatment. In connection with the acquisition, we incurred a pre-tax non-cash charge of \$115 million, or \$.45 per diluted share, for acquired in-process research and development.
- In December 2006, we sold the blood glucose monitoring (“BGM”) product line. Following the sale, prior period Consolidated Statements of Income and Cash Flows were restated to separately present the results of the BGM product line as discontinued operations.

2006

- In February 2006, we acquired GeneOhm Sciences, Inc. (“GeneOhm”). In connection with the acquisition, we incurred a pre-tax non-cash charge of \$53 million, or \$.21 per diluted share, for acquired in-process research and development.

Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products with higher gross profit margins across our business segments, and continue to improve operating efficiency and organizational effectiveness. Numerous factors can affect our ability to achieve these goals including, without limitation, economic conditions in the United States and elsewhere, increased competition and healthcare cost containment initiatives.

We believe several important factors relating to our business tend to reduce the impact on BD of any potential economic or political events in countries in which we do business, including the effects of possible healthcare system reforms. For example, since many of our products are used in essential medical care, demand for such products tends not to be significantly affected by economic fluctuations. Other factors include the international nature of our business and our ability to meet the needs of the worldwide healthcare industry with cost-effective and innovative products.

In 2007, general inflation did not have a material impact on our overall operations. However, it is possible that general inflation rates will rise in 2008 and beyond, and could have a greater impact on worldwide economies and, consequently, on BD. BD purchases supplies of resins, which are oil-based components used in the manufacture of certain products. During 2007, we incurred slightly higher resin purchase costs than the prior year, primarily due to increases in world oil prices during the late summer 2006. Such increases did not have a significant impact on our 2007 operating results. Any significant increases in resin purchase costs could impact future operating results.

Our anticipated revenue growth over the next three years is expected to come from the following:

- Business growth and expansion among all segments; and
- Development in each business segment of new products and services that provide increased benefits to patients, healthcare workers and researchers.

Results of Continuing Operations

Medical Segment

Medical revenues in 2007 of \$3.4 billion increased \$314 million, or 10%, over 2006, which includes an estimated impact of unfavorable foreign currency translation of 3 percentage points.

The following is a summary of revenues by organizational unit:

(millions of dollars)	2007	2006	Estimated Foreign	
			Total Change	Exchange Impact
Medical Surgical Systems	\$1,864	\$1,749	7%	2%
Diabetes Care	696	657	6%	2%
Pharmaceutical Systems	792	640	24%	6%
Ophthalmic Systems	69	62	11%	4%
Total Revenues*	\$3,421	\$3,107	10%	3%

* Amounts may not add due to rounding.

Medical revenues reflect the growth of the Pharmaceutical Systems unit and the continued global conversion to safety-engineered products. The Pharmaceutical Systems unit grew by 24%, reflecting the increased use of prefillable syringes by pharmaceutical companies to market new vaccines and bio-tech drugs, especially in the United States. Revenue growth in the Medical Surgical Systems unit was primarily driven by the growth in safety-engineered products and prefilled flush syringes. Sales of safety-engineered products increased 6% in the United States and 30% internationally. For 2008, we expect the full-year revenue growth for the Medical Segment to be about 8%.

Medical operating income was \$972 million, or 28.4% of Medical revenues, in 2007, as compared with \$864 million, or 27.8% in 2006. The increase in operating income as a percentage of revenues reflects gross margin improvement from increased sales of products that have higher overall gross profit margins, in particular, safety-engineered products and pen needles, as well as favorable manufacturing efficiencies associated with higher volumes and increased leverage on selling and administrative expenses. These improvements were slightly offset by manufacturing start-up costs. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Medical revenues in 2007 declined to 18.9% of revenues from 19.6% of revenues in 2006, primarily due to tight expense controls over base spending. Research and development expenses in 2007 increased \$16 million, or 17%, reflecting continued investment in the development of new products and platforms, and included investments in additional resources to enhance our product development process.

Diagnostics Segment

Diagnostics revenues in 2007 of \$1.9 billion increased \$190 million, or 11%, over 2006, which reflected an estimated favorable impact of foreign currency translation of about 2 percentage points.

The following is a summary of revenues by organizational unit:

(millions of dollars)	2007	2006	Estimated Foreign	
			Total Change	Exchange Impact
Preanalytical Systems	\$1,007	\$ 928	9%	3%
Diagnostic Systems	898	787	14%	2%
Total Revenues	\$1,905	\$1,715	11%	2%

Revenue growth in the Preanalytical Systems unit was driven by the continued conversion to safety-engineered products, which accounted for sales of \$718 million as compared with \$627 million in the prior year. Sales of safety-engineered products reflected growth of 9% in the United States, which benefited from *BD Vacutainer* Push Button Blood Collection Set conversion activity, and 25% internationally. The Diagnostics Systems unit experienced solid worldwide sales of its automated diagnostic platforms, including the molecular *BD ProbeTec* and *BD Viper* systems, along with solid growth of its *BD BACTEC* blood culture and TB systems and the *BD Phoenix* ID/AST platform. Those platforms reported combined incremental sales of \$35 million over 2006. In addition, the Diagnostic Systems revenue growth includes \$88 million of revenues from TriPath and \$13 million of incremental revenues from GeneOhm. Sales of flu diagnostic tests declined \$36 million in fiscal 2007 compared with 2006, primarily due to relatively mild flu seasons in both the United States and Japan and the termination of our supply arrangement with our Japanese supplier. For 2008, we expect full year revenue growth for the Diagnostics Segment to be about 9%.

Diagnostics operating income was \$343 million, or 18.0% of Diagnostics revenues in 2007, compared with \$390 million, or 22.8% in 2006. Segment operating income reflects the in-process research and development charges of \$115 million in 2007 related to the TriPath acquisition and \$53 million in 2006 related to the GeneOhm acquisition. The Diagnostics Segment experienced a slight improvement in gross profit margin from sales growth of products that have higher overall gross profit margins, in particular, safety-engineered products and the *BD ProbeTec* system. These improvements were slightly offset by manufacturing start-up costs. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Diagnostics revenues in 2007 was higher than the comparable amount in 2006 primarily due to the impact of TriPath and GeneOhm. Research and development expense increased \$33 million, or 39%, reflecting new spending associated with these two acquisitions and overall increased investment in new product development.

Biosciences Segment

Biosciences revenues in 2007 of \$1.0 billion increased \$118 million, or 13%, over 2006, which reflected an estimated impact of favorable foreign currency translation of 3 percentage points.

The following is a summary of revenues by organizational unit:

(millions of dollars)	2007	2006	Estimated Foreign	
			Total Change	Exchange Impact
Immunocytometry Systems	\$ 588	\$503	17%	3%
Discovery Labware	278	256	9%	2%
Pharming	168	157	7%	2%
Total Revenues	\$1,034	\$916	13%	3%

Revenue growth in the Immunocytometry Systems unit reflects strong sales of instruments and flow cytometry reagents, driven by increased demand for research analyzers and clinical reagents. Revenue growth in the Discovery Labware unit reflects strong sales of bionutrients and overall market growth. For 2008, we expect the full year revenue growth for the Biosciences Segment to be about 8 to 9%.

Biosciences operating income was \$259 million, or 25.0% of Biosciences revenues in 2007, compared with \$222 million, or 24.2% in 2006. Segment operating income includes an in-process research and development charge of \$7 million in 2007. The increase in operating income, as a percentage of revenues, reflects gross profit improvement from relatively higher sales growth of products that have higher overall gross profit margins and the favorable impact of foreign currency translation. These improvements were offset by manufacturing start-up costs. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Biosciences revenues was 24.0% versus 25.3% in 2006. Higher sales and continued tight expense control were the key contributors to the increased expense leverage. Research and development expense in 2007 increased \$7 million, or 9.0%, reflecting spending on new product development and advanced technology, particularly in the Immunocytometry Systems unit.

Geographic Revenues

Revenues in the United States in 2007 of \$3.0 billion increased 11%. U.S. sales of safety-engineered devices were approximately \$982 million in 2007, compared with \$917 million in 2006. Growth was also led by strong sales of prefilled flush syringes, prefillable syringes and immunocytometry instruments and reagents. U.S. revenue growth also included \$88 million of revenues from TriPath.

Revenues outside the United States in 2007 increased 11% to \$3.3 billion, reflecting an estimated impact of favorable foreign currency translation of 5 percentage points. Growth was led by solid sales in our European, Asia Pacific and Canadian regions in 2007. International sales of safety-engineered devices were approximately \$409 million in 2007, compared with \$324 million in 2006.

Gross Profit Margin

Gross profit margin was 51.7% in 2007, compared with 51.3% in 2006. Gross profit margin in the current year as compared with the prior year reflected an estimated 0.6% improvement relating to increased sales of products with relatively higher margins as well as productivity gains. These improvements were partially offset by an estimated 0.2% impact from manufacturing start-up costs. We expect gross profit margin in 2008 to be about the same as in 2007. Expected improvements are anticipated to be offset by increased resin and steel costs as well as manufacturing start-up costs in 2008.

Operating Expenses

Selling and administrative expense was \$1.6 billion in 2007 compared with \$1.4 billion in 2006, or 25.2% of revenues in both years. Aggregate expenses for 2007 reflect base spending increases of \$62 million and expenses of \$40 million associated with the GeneOhm and TriPath operations. Increases in selling and administrative expense in 2007 also reflected the absence of proceeds from insurance settlements of \$17 million received in the prior year in connection with our previously-owned latex glove business, as well as an unfavorable foreign exchange impact of \$35 million. Selling and administrative expense as a percentage of revenues is expected to decrease, on a reported basis, by about 70 basis points for 2008.

Research and development ("R&D") expense in 2007 was \$360 million, or 5.7% of revenues, compared with \$302 million, or 5.3% of revenues, in 2006. The increase in R&D expenditures includes spending for new programs in each of our segments, as previously discussed. R&D expense is expected to increase about 11% for 2008.

Operating Income

Operating margin in 2007 was 18.9% of revenues, compared with 19.9% in 2006. Operating income of \$1.2 billion in 2007 reflected \$122 million of acquired in-process R&D charges, as further discussed above. Operating income of \$1.1 billion in 2006 included \$53 million of acquired in-process R&D charges, partially offset by \$17 million of insurance settlement proceeds, as discussed above. We expect operating margin to increase 240 to 250 basis points, with 190 basis points attributable to the acquired in-process R&D charges in 2007.

Non-Operating Expense and Income

Interest expense was \$46 million in 2007, compared with \$66 million in 2006. The decrease reflected lower debt and higher levels of capitalized interest. Interest income was \$46 million in 2007, compared with \$59 million in 2006, resulting from lower cash balances.

Income Taxes

The effective tax rate in 2007 was 28.9% compared with the prior year's rate of 27.6%. The 2007 rate reflected the non-deductibility of the acquired in-process R&D charges of \$122 million, which were partially offset by the impact of approximately 0.3% resulting from the retroactive reinstatement of the research and experimentation tax credit. The 2006 rate reflected the non-deductibility of the acquired in-process R&D charge of \$53 million, as well as the impact relating to the proceeds received from insurance settlements of approximately 0.2%. In 2008, we expect our effective tax rate to be about 27%.

Income and Diluted Earnings per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations in 2007 were \$856 million and \$3.36, respectively. The acquired in-process R&D charges decreased income from continuing operations and diluted earnings per share from continuing operations in the aggregate by \$122 million and by \$.48, respectively, in 2007. Income from continuing operations and diluted earnings per share from continuing operations in 2006 were \$815 million and \$3.18, respectively. The acquired in-process R&D charge decreased income from continuing operations and diluted earnings per share from continuing operations by \$53 million and by \$.21, respectively, in 2006.

Discontinued Operations

In September 2006, the Company announced a plan to exit the blood glucose monitoring market. The Company recorded a pre-tax charge of \$63 million in connection with its decision to exit the BGM product line. During the first quarter of 2007, the Company received an unsolicited offer for the purchase of the BGM product line. In December 2006, the Company sold the product line for \$20 million. Following the sale, prior period Consolidated Statements of Income and Cash Flows were restated to separately present the results of the BGM product line as discontinued operations. The September 30, 2006 Consolidated Balance Sheet was not restated. See Note 3 of the Notes to Consolidated Financial Statements for additional discussion.

Financial Instrument Market Risk

We selectively use financial instruments to manage the impact of foreign exchange rate and interest rate fluctuations on earnings. The counterparties to these contracts are highly rated financial institutions. We do not enter into financial instruments for trading or speculative purposes.

We have foreign currency exposures throughout Europe, Asia Pacific, Canada, Japan and Latin America. We face transactional currency exposures that arise when we enter into transactions in non-hyperinflationary countries, generally on an intercompany basis, that are denominated in currencies other than our functional currency. We hedge substantially all such foreign exchange exposures primarily through the use of forward contracts and currency options. We also face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of a reporting period. To partially protect against adverse foreign exchange rate movements, we purchase option and forward contracts to hedge certain forecasted sales that are denominated in foreign currencies. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. For foreign currency derivative instruments, market risk is determined by calculating the impact on fair value of an assumed change in foreign exchange rates relative to the U.S. dollar. Fair values were estimated based on market prices, when available, or dealer quotes. The reduction in fair value of our purchased option contracts is limited to the option's fair value. With respect to the derivative instruments outstanding at September 30, 2007, a 10% appreciation of the U.S. dollar over a one-year period would increase pre-tax earnings by \$52 million, while a 10% depreciation of the U.S. dollar would decrease pre-tax earnings by \$10 million.

Comparatively, considering our derivative instruments outstanding at September 30, 2006, a 10% appreciation of the U.S. dollar over a one-year period would have increased pre-tax earnings by \$68 million, while a 10% depreciation of the U.S. dollar would have decreased pre-tax earnings by \$3 million. These calculations do not reflect the impact of exchange gains or losses on the underlying positions that would substantially offset the results of the derivative instruments.

Our primary interest rate exposure results from changes in short-term U.S. dollar interest rates. Our debt and interest-bearing investments at September 30, 2007, are substantially all U.S. dollar-denominated. Therefore, transaction and translation exposure relating to such instruments is minimal. When managing interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate instruments. We may enter into interest rate swaps to help maintain this balance and manage debt and interest-bearing investments in tandem, since these items have an offsetting impact on interest rate exposure. For interest rate derivative instruments, market risk is determined by calculating the impact to fair value of an assumed change in interest rates across all maturities. Fair values are estimated based on dealer quotes. A change in interest rates on short-term debt and interest-bearing investments is assumed to impact earnings and cash flow, but not fair value because of the short maturities of these instruments. A change in interest rates on long-term debt is assumed to impact fair value but not earnings or cash flow because the interest on such obligations is fixed. Based on our overall interest rate exposure at September 30, 2007 and 2006, a change of 10% in interest rates would not have a material effect on our earnings or cash flows over a one-year period. An increase of 10% in interest rates would decrease the fair value of our long-term debt and interest rate swaps at September 30, 2007 and 2006 by approximately \$37 million and \$39 million, respectively. A 10% decrease in interest rates would increase the fair value of our long-term debt and interest rate swaps at September 30, 2007 and 2006 by approximately \$41 million and \$33 million, respectively.

Liquidity and Capital Resources

Net Cash Flows from Continuing Operating Activities

Net cash provided by continuing operating activities, which continues to be our primary source of funds to finance operating needs and capital expenditures, was \$1.2 billion in 2007, compared with \$1.1 billion in 2006.

Net Cash Flows from Continuing Investing Activities

Net cash used for continuing investing activities in 2007 was \$1.0 billion, compared with \$784 million in 2006. Acquisitions of businesses of \$340 million in 2007 represented the net cash paid for the TriPath acquisition. Capital expenditures were \$556 million in 2007, compared with \$457 million in 2006. Medical capital spending of \$353 million and Diagnostics capital spending of \$114 million in 2007 related primarily to various capacity expansions. Biosciences capital spending of \$73 million in 2007 included spending on manufacturing capacity expansions. In 2008, capital expenditures are expected to be in the \$600 to \$650 million range, reflecting investments in various manufacturing capacity and facility expansions.

Net Cash Flows from Continuing Financing Activities

Net cash used for financing activities was \$726 million in 2007, as compared with \$342 million in 2006, and included the repurchase of shares of our common stock for approximately \$450 million, compared with approximately \$449 million in 2006. At September 30, 2007, approximately 11.1 million common shares remained available for purchase, consisting of 1.1 million shares remaining under a November 2005 Board of Directors' authorization to repurchase up to 10 million common shares, plus an additional 10 million shares that were authorized for repurchase by the Board of Directors in July 2007. For 2008, we expect that cash used to repurchase common shares will be about \$450 million. Total debt at September 30, 2007, was \$1.2 billion compared with \$1.4 billion at September 30, 2006. Short-term debt decreased to 18% of total debt at year-end, from 31% at the end of 2006. Floating rate debt was 36% of total debt at the end of 2007 and 46% at the end of 2006. Our weighted average cost of total debt at the end of 2007 was 5.7%, up from 5.5% at the end of 2006. Debt-to-capitalization at year-end improved to 20.9% from 25.8% last year.

We have in place a commercial paper borrowing program that is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were \$200 million at September 30, 2007. We maintain a \$1.0 billion syndicated credit facility in order to provide backup support for our commercial paper program and for other general corporate purposes. This credit facility expires in December 2012 and includes a single financial covenant that requires BD to maintain an interest expense coverage ratio (ratio of earnings before income taxes, depreciation and amortization to interest expense) of not less than 5-to-1 for the most recent four consecutive fiscal quarters. On the last eight measurement dates, this ratio had ranged from 17-to-1 to 23-to-1. There were no borrowings outstanding under this facility at September 30, 2007. In addition, we have informal lines of credit outside the United States.

At September 30, 2007, our long-term debt was rated "A2" by Moody's and "A+" by Standard and Poor's, and our commercial paper ratings were "P-1" by Moody's and "A-1" by Standard and Poor's. Given the availability of the various credit facilities and our strong credit ratings, we continue to have a high degree of confidence in our ability to refinance maturing short-term and long-term debt, as well as to incur substantial additional debt, if required.

BD's ability to generate cash flow from operations, issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms could be adversely affected in the event there was a material decline in the demand for BD's products, deterioration in BD's key financial ratios or credit ratings or other significantly unfavorable changes in conditions. While a deterioration in the Company's credit ratings would increase the costs associated with maintaining and borrowing under its existing credit arrangements, such a downgrade would not affect the Company's ability to draw on these credit facilities, nor would it result in an acceleration of the scheduled maturities of any outstanding debt.

Contractual Obligations

In the normal course of business, we enter into contracts and commitments that obligate us to make payments in the future. The table below sets forth BD's significant contractual obligations and related scheduled payments:

(millions of dollars)	Total	2009 to 2008	2011 to 2010	2013 and 2012	Thereafter
Short-term debt	\$ 208	\$208	\$ —	\$ —	\$ —
Long-term debt ^(A)	1,594	54	301	85	1,154
Operating leases	153	46	59	32	16
Purchase obligations ^(B)	365	296	50	19	—
Total ^(C)	\$2,320	\$604	\$410	\$136	\$1,170

(A) Long-term debt obligations include expected principal and interest obligations, including interest rate swaps. The interest rate forward curve at September 30, 2007 was used to compute the amount of the contractual obligation for variable rate debt instruments and swaps.

(B) Purchase obligations are for purchases made in the normal course of business to meet operational and capital requirements.

(C) Required funding obligations for 2008 relating to pension and other postretirement benefit plans are not expected to be material.

2006 Compared With 2005

Worldwide revenues in 2006 of \$5.7 billion increased 7% from 2005 and reflected estimated volume increases of 7%, an estimated decrease due to unfavorable foreign currency translation of 1%, and estimated price increases of less than 1%.

Medical Segment

Medical revenues in 2006 of \$3.1 billion increased \$222 million, or 8%, over 2005.

The following is a summary of revenues by organizational unit:

(millions of dollars)	2006	2005	Total Change*	Estimated Foreign Exchange Impact
Medical Surgical Systems	\$1,749	\$1,661	5%	—
Diabetes Care	657	600	9%	(1%)
Pharmaceutical Systems	640	563	14%	(3%)
Ophthalmic Systems	62	60	3%	(2%)
Total Revenues*	\$3,107	\$2,884	8%	(1%)

* Amounts may not calculate due to rounding.

Medical revenue growth was driven by the continued conversion to safety-engineered products, which accounted for sales of \$613 million, as compared with \$571 million in the prior year, reflecting growth of 6% in the United States and 16% internationally. Revenue growth in the Medical Surgical Systems unit of this segment was primarily driven by the growth in safety-engineered products and prefilled flush syringes. Revenue growth in the Pharmaceutical Systems unit was driven by a 26% increase in sales in the United States. The Diabetes Care unit's revenue growth reflected strong sales of pen needles worldwide.

Medical operating income was \$864 million, or 27.8% of Medical revenues, in 2006, as compared with \$748 million, or 25.9% in 2005. The Segment's gross profit margin in 2006 reflected improvement associated with relatively higher sales growth of products that have higher overall gross profit margins, in particular, safety-engineered products and pen needles, as well as favorable manufacturing efficiencies associated with higher volumes. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Medical revenues in 2006 was slightly lower compared with 2005, primarily due to tight expense controls over base spending. Research and development expense in 2006 increased \$7 million, or 8%, reflecting continued investment in the development of new products and platforms.

Diagnostics Segment

Diagnostics revenues in 2006 of \$1.7 billion increased \$83 million, or 5%, over 2005, which reflected an estimated unfavorable impact of foreign currency translation of about 1 percentage point.

The following is a summary of revenues by organizational unit:

(millions of dollars)	2006	2005	Total Change	Estimated Foreign Exchange Impact
Preanalytical Systems	\$ 928	\$ 855	9%	—
Diagnostic Systems	787	777	1%	(1%)
Total Revenues	\$1,715	\$1,632	5%	(1%)

Revenue growth in the Preanalytical Systems unit was driven by the continued conversion to safety-engineered products, which accounted for sales of \$627 million, as compared with \$543 million in 2005. Sales of safety-engineered products reflected growth of 13% in the United States, which benefited from *BD Vacutainer* Push Button Blood Collection Set conversion activity, and 20% internationally. The Diagnostic Systems unit experienced solid worldwide sales of its automated diagnostic platforms, including the molecular *BD ProbeTec* ET, *BD BACTEC*, and the *BD Phoenix* ID/AST. These platforms reported combined incremental sales of \$33 million over 2005. Revenues for GeneOhm, which was acquired in February 2006, totaled \$8 million. Sales of flu diagnostic tests declined by approximately \$11 million in fiscal 2006 compared with 2005, primarily due to a relatively mild flu season in both Japan and the United States.

Diagnostics operating income was \$390 million, or 22.8% of Diagnostics revenues, in 2006, compared with \$403 million, or 24.7%, in 2005. Segment operating income for 2006 reflects the acquired in-process research and development charge of \$53 million as well as the operating results of GeneOhm, which in the aggregate, reduced operating income as a percentage of Diagnostics revenues by approximately 5%. The Diagnostics Segment experienced slight gross profit margin improvement reflecting higher prices and productivity, which was substantially offset by the impact of the recently acquired GeneOhm products, which have lower overall gross profit margins, and lower sales growth of flu diagnostic products, which have higher overall gross profit margins. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Diagnostics revenues in 2006 was lower compared with 2005 primarily due to tight controls on spending, which more than offset the incremental GeneOhm expenses. Research and development expense in 2006 increased \$6 million, or 7%, reflecting new spending for product development associated with the GeneOhm acquisition.

Biosciences Segment

Biosciences revenues in 2006 of \$916 million increased \$92 million, or 11%, over 2005, which reflected an estimated impact of unfavorable foreign currency translation of 1 percentage point.

The following is a summary of revenues by organizational unit:

(millions of dollars)	2006	2005	Estimated Foreign	
			Total Change*	Exchange Impact
Immunocytometry Systems	\$503	\$452	11%	(1%)
Discovery Labware	256	231	11%	(1%)
Pharmingen	157	141	12%	(1%)
Total Revenues	\$916	\$824	11%	(1%)

* Amounts may not calculate due to rounding.

Revenue growth in the Immunocytometry Systems unit reflected strong sales of instruments and flow cytometry reagents, driven by increased demand for research and clinical analyzers. Revenue growth rates in the Immunocytometry Systems and Pharmingen units were favorably impacted by the adverse effect a cancellation of a distribution agreement had on revenues in 2005. As a result of an inventory repurchase obligation to this distributor upon termination of the arrangement, certain sales made to this distributor in the latter part of 2005 (\$5 million in Immunocytometry Systems and \$12 million in Pharmingen) were not recognized as revenue. In addition, sales in 2006 were favorably impacted by higher average selling prices as a result of terminating the arrangement. Revenue growth in the Discovery Labware unit resulted primarily from strong sales of bionutrients and market share gains.

Biosciences operating income was \$222 million, or 24.2% of Biosciences revenues in 2006, compared with \$186 million, or 22.5% in 2005. The increase in operating income, as a percentage of revenues, reflects gross profit improvement from the favorable impact of terminating a distribution agreement in 2005, increased operating efficiencies, as well as relatively higher sales growth of products that have higher overall gross profit margins. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Biosciences revenues was lower compared with 2005, primarily due to higher revenues and the absence of \$8 million of costs incurred in 2005 associated with the termination of the distribution agreement, mentioned above. Research and development expense in 2006 increased \$8 million, or 13%, reflecting spending on new product development and advanced technology, particularly in the Immunocytometry Systems unit and bioimaging products.

Geographic Revenues

Revenues in the United States in 2006 of \$2.7 billion increased 9%. U.S. sales of safety-engineered devices were approximately \$917 million in 2006, compared with \$842 million in 2005. Growth was also led by strong sales of diabetes care products, prefilled flush syringes and prefillable syringes. Revenues of immunocytometry instruments and reagents also demonstrated good growth.

Revenues outside the United States in 2006 increased 6% to \$3 billion, reflecting an estimated impact of unfavorable foreign currency translation of 2 percentage points. Growth was led by strong sales in our Asia Pacific, Canadian and European regions in 2006. International sales of safety-engineered devices were approximately \$324 million in 2006, compared with \$273 million in 2005.

Gross Profit Margin

Gross profit margin was 51.3% in 2006, compared with 50.9% in 2005. Gross profit margin in 2006 reflected an estimated 1.0% improvement relating to increased sales growth of products with relatively higher margins and to productivity gains. These improvements were partially offset by an estimated 0.2% impact from foreign currency translation, an estimated 0.3% unfavorable impact of higher raw material costs and 0.1% relating to an increase in share-based compensation.

Operating Expenses

Selling and administrative expense of \$1.4 billion in 2006 was 25.2% of revenues, compared with \$1.4 billion or 26.0% of revenues in 2005. Aggregate expenses for 2006 reflect base spending increases of \$49 million and expenses associated with recent acquisitions, primarily GeneOhm, of \$17 million. Selling and administrative expense in 2006 also reflected increases primarily in share-based compensation expense of \$25 million. These increases were partially offset by a favorable foreign exchange impact of \$13 million and by proceeds from insurance settlements of \$17 million received in connection with our previously-owned latex glove business.

Research and development expense in 2006 was \$302 million, or 5.3% of revenues, compared with \$268 million, or 5.0% of revenues, in 2005. The increase in R&D expenditures reflected spending for new programs in each of our segments, as previously discussed.

Non-Operating Expense and Income

Interest expense was \$66 million in 2006, compared with \$56 million in 2005. The increase reflected higher debt levels and the impact of higher interest rates on floating rate debt and on fixed-to-floating interest rate swap transactions. Such swap transactions consist of fair value hedges of certain fixed-rate instruments under which the difference between fixed and floating interest rates is exchanged at specified intervals. Interest income was \$59 million in 2006, compared with \$36 million in 2005, and reflected higher interest rates and cash balances.

Income Taxes

The effective tax rate in 2006 was 27.6% and reflected the unfavorable impact of the non-deductibility of the acquired in-process R&D charge. The effective tax rate in 2005 was 31.3% and reflected a 7.7% increase relating to the charge in 2005 attributable to the planned repatriation of earnings in 2006 under the American Jobs Creation Act of 2004. In addition, the effective tax rate in 2005 reflected a 1.0% benefit due to the reversal of tax accruals in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

Income and Diluted Earnings per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations in 2006 were \$815 million and \$3.18, respectively. The in-process R&D charge decreased income from continuing operations and diluted earnings per share from continuing operations by \$53 million and by \$.21 in 2006. Income from continuing operations and diluted earnings per share from continuing operations in 2005 were \$713 million and \$2.73, respectively. The tax repatriation charge decreased income from continuing operations by \$77 million and diluted earnings per share from continuing operations by \$.30 in 2005.

Liquidity and Capital Resources

Net Cash Flows from Continuing Operating Activities

Net cash provided by continuing operating activities was \$1.1 billion in 2006, reduced from \$1.2 billion in 2005, reflecting higher inventory levels and higher income tax payments, including taxes associated with the repatriation of earnings, as discussed further below.

Net Cash Flows from Continuing Investing Activities

Net cash used for continuing investing activities in 2006 was \$784 million, compared with \$380 million in 2005. Acquisitions of businesses of \$231 million in 2006 represented the net cash paid for the GeneOhm acquisition. Capital expenditures were \$457 million in 2006, compared with \$316 million in 2005. Medical capital spending of \$269 million and Diagnostics capital spending of \$105 million related primarily to various capacity expansions. Biosciences capital spending of \$39 million included spending on manufacturing capacity expansions.

Net Cash Flows from Continuing Financing Activities

Net cash used for financing activities was \$342 million in 2006, as compared with \$516 million in 2005, and included the repurchase of shares of our common stock for approximately \$449 million, compared with approximately \$550 million in 2005. Total debt at September 30, 2006, was \$1.4 billion compared with \$1.3 billion at September 30, 2005. Short-term debt increased to 31% of total debt at year-end, from 16% at the end of 2005. Floating rate debt was 46% of total debt at the end of 2006 and 41% at the end of 2005. Our weighted average cost of total debt at the end of 2006 was 5.5%, up from 5.3% at the end of 2005, due to higher short-term interest rates. Debt-to-capitalization at year-end improved to 25.8% in 2006 from 27.1% in 2005.

The American Jobs Creation Act of 2004 (the "AJCA") was signed into law in October 2004. The AJCA creates a temporary incentive for U.S. multinationals to repatriate accumulated income earned outside the United States. As a result of the passage of the AJCA, we repatriated approximately \$1.3 billion in 2006 in accordance with our planned repatriation under the AJCA. Uses of the repatriated funds include cash expenditures for compensation and benefits to existing and newly hired U.S. workers, U.S. infrastructure and capital investments and other activities as permitted under the AJCA.

Critical Accounting Policies

The preparation of the consolidated financial statements requires management to use estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Some of those judgments can be subjective and complex and, consequently, actual results could differ from those estimates. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. For any given estimate or assumption made by management, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Actual results that differ from management's estimates could have an unfavorable effect on our consolidated financial statements. Management believes the following critical accounting policies reflect the more significant judgments and estimates used in the preparation of the consolidated financial statements.

Revenue Recognition

Revenue from product sales is recognized when title and risk of loss pass to the customer. We recognize revenue for certain instruments sold from the Biosciences segment upon installation at a customer's site. Based upon terms of the sales agreements, the Biosciences segment recognizes revenue in accordance with Emerging Issues Task Force No. 00-21, "Revenue Arrangements with Multiple Deliverables." These sales agreements have multiple deliverables, and as such are divided into separate units of accounting. Revenue is recognized upon the completion of each deliverable based on the relative fair values of items delivered.

BD's domestic businesses sell products primarily to distributors who resell the products to end-user customers. We provide rebates to distributors that sell to end-user customers at prices determined under a contract between BD and the end-user customer. Provisions for rebates, as well as sales discounts and returns, are accounted for as a reduction of revenues when revenue is recognized.

Impairment of Assets

Pursuant to SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill and indefinite-lived intangible assets are subject to impairment reviews at least annually, or whenever indicators of impairment arise. Intangible assets other than goodwill and indefinite-lived intangible assets and other long-lived assets are reviewed for impairment in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." Impairment reviews are based on a cash flow approach that requires significant management judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, appropriate discount rates and other assumptions and estimates. The estimates and assumptions used are consistent with BD's business plans. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of the asset, and potentially result in different impacts to BD's results of operations. Actual results may differ from management's estimates.

Investments

We hold equity interests in companies having operations or technology in areas within or adjacent to BD's strategic focus. For some of these companies that are publicly traded, market prices are available. However, for those companies that are not publicly traded, fair value is difficult to determine. We write down an investment when management believes an investment has experienced a decline in value that is other than temporary. Future adverse changes in market conditions or poor operating results of the underlying investments could result in an inability to recover the carrying value of the investments, thereby possibly requiring impairment charges in the future.

Tax Valuation Allowances

BD maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset.

Contingencies

We are involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability, antitrust, and environmental matters, as further discussed in Note 12 of the Notes to Consolidated Financial Statements. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. In accordance with U.S. generally accepted accounting principles, we establish accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). A determination of the amount of accruals, if any, for these contingencies is made after careful analysis of each individual issue and, when appropriate, is developed after consultation with outside counsel. The accruals may change in the future due to new developments in each matter or changes in our strategy in dealing with these matters.

Given the uncertain nature of litigation generally, we are not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which we are a party. In view of these uncertainties, we could incur charges in excess of any currently established accruals and, to the extent available, excess liability insurance. Accordingly, in the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on BD's consolidated results of operations and consolidated net cash flows.

Benefit Plans

We have significant net pension and postretirement benefit costs that are measured using actuarial valuations. Inherent in these valuations are key assumptions including discount rates and expected return on plan assets. We evaluate these key assumptions at least annually on a plan- and country-specific basis. We consider current market conditions, including changes in interest rates and market returns, in selecting these assumptions. Changes in the related net pension and post-retirement benefits costs may occur in the future due to changes in assumptions.

The discount rate is selected to reflect the prevailing rate on September 30 based on investment grade bonds and other factors. Specifically, for the U.S. pension plan, we use an actuarially-determined yield curve to determine the discount rate. We increased our discount rate for the U.S. pension and postretirement plans at September 30, 2007 from 5.95% to 6.35% and increased the rate at September 30, 2006 from 5.5% to 5.95%.

To determine the expected long-term rate of return on pension plan assets, we consider the historical and expected returns on various plan asset classes, as well as current and expected asset allocations. At September 30, 2007, the one-year rate of return on assets for our U.S. pension plans was 14.6%, the five-year rate of return was 13.0%, and the ten-year rate of return was 6.5%. We believe that these results, in connection with our current and expected asset allocation, support our assumed long-term return of 8.0% on those assets.

Sensitivity to changes in key assumptions for our U.S. pension and postretirement plans are as follows:

- Discount rate—A change of plus (minus) 25 basis points, with other assumptions held constant, would have an estimated \$7 million favorable (unfavorable) impact on the total U.S. net pension and postretirement benefit plan cost.
- Expected return on plan assets—A change of plus (minus) 25 basis points, with other assumptions held constant, would have an estimated \$2 million favorable (unfavorable) impact on U.S. pension plan cost.

Stock-Based Compensation

Compensation cost relating to share-based payment transactions is recognized in net income using a fair value measurement method, in accordance with SFAS No. 123(R). SFAS No. 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations as compensation expense (based on their fair values) over the vesting period of the awards. We determine the fair value of certain share-based awards using a lattice-based binomial option valuation model that incorporates certain assumptions, such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. See Note 13 of the Notes to Consolidated Financial Statements for additional discussion.

Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time-to-time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in this report and filings with the Securities and Exchange Commission and in our other reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures.

All statements that address operating performance or events or developments that we expect or anticipate will occur in the future—including statements relating to volume growth, sales and earnings per share growth and statements expressing views about future operating results—are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events and developments or otherwise.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements:

- Regional, national and foreign economic factors, including inflation and fluctuations in interest rates and foreign currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins, as well as competition in certain markets.
- We operate in a highly competitive environment. New product introductions by our current or future competitors (for example, new forms of drug delivery) could adversely affect our ability to compete in the global market. Patents attained by competitors, particularly as patents on our products expire, may also adversely impact our competitive position. Certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs. New entrants may also appear.
- Changes in domestic and foreign healthcare industry practices and regulations resulting in increased pricing pressures, including the continued consolidation among healthcare providers; trends toward managed care and healthcare cost containment; and government laws and regulations relating to sales and promotion, reimbursement and pricing generally.
- The effects, if any, of governmental and media activities regarding the business practices of group purchasing organizations, which negotiate product prices on behalf of their member hospitals with BD and other suppliers.

- Fluctuations in the cost and availability of oil-based resins and other raw materials and the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers) and the potential adverse effects of any disruption in the availability of such raw materials.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Adoption of or changes in government laws and regulations affecting domestic and foreign operations, including those relating to trade, monetary and fiscal policies, taxation, environmental matters, sales practices, price controls, licensing and regulatory approval of new products, regulatory requirements for products in the postmarketing phase, or changes in enforcement practices with respect to any such laws and regulations. In particular, environmental laws, particularly with respect to the emission of greenhouse gases, are becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes.
- Fluctuations in U.S. and international governmental funding and policies for life sciences research.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of encountering infringement claims by competitors with respect to patent or other intellectual property rights, all of which can preclude or delay commercialization of a product.
- Pending and potential litigation or other proceedings adverse to BD, including antitrust claims, product liability claims, patent infringement claims and the availability or collectibility of insurance.
- The effects, if any, of adverse media exposure or other publicity regarding BD's business or operations.
- Our ability to achieve earnings forecasts, which are generated based on projected volumes and sales of many product types, some of which are more profitable than others. There can be no assurance that we will achieve any projected level or mix of product sales.
- The effect of market fluctuations on the value of assets in BD's pension plans and the possibility that BD may need to make additional contributions to the plans as a result of any decline in the value of such assets.
- Our ability to effect infrastructure enhancements and incorporate new systems technologies into our operations.
- Product efficacy or safety concerns resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (or foreign counterparts) or declining sales.
- Economic and political conditions in international markets, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders and expropriation of assets by a government.
- The effects of natural disasters, including hurricanes or pandemic diseases, on our ability to manufacture our products, particularly where production of a product line is concentrated in one or more plants, or on our ability to source components from suppliers that are needed for such manufacturing.
- Our ability to penetrate developing and emerging markets, which also depends on economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities, distribution networks, sales equipment and technology.
- The impact of business combinations, including acquisitions and divestitures, both internally for BD and externally in the healthcare industry.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

Management's Responsibilities

The following financial statements have been prepared by management in conformity with U.S. generally accepted accounting principles and include, where required, amounts based on the best estimates and judgments of management. The integrity and objectivity of data in the financial statements and elsewhere in this Annual Report are the responsibility of management.

In fulfilling its responsibilities for the integrity of the data presented and to safeguard the Company's assets, management employs a system of internal accounting controls designed to provide reasonable assurance, at appropriate cost, that the Company's assets are protected and that transactions are appropriately authorized, recorded and summarized. This system of control is supported by the selection of qualified personnel, by organizational assignments that provide appropriate delegation of authority and division of responsibilities, and by the dissemination of written policies and procedures.

Management's Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Act of 1934. Management conducted an assessment of the effectiveness of internal control over financial reporting based on the criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment and those criteria, management concluded that internal control over financial reporting was effective as of September 30, 2007.

This control structure is further reinforced by a program of internal audits, including a policy that requires responsive action by management.

The Board of Directors monitors the internal control system, including internal accounting and financial reporting controls, through its Audit Committee, which consists of six independent Directors. The Audit Committee meets periodically with the independent registered public accounting firm, the internal auditors and management to review the work of each and to satisfy itself that they are properly discharging their responsibilities. The independent registered public accounting firm and the internal auditors have full and free access to the Audit Committee and meet with its members, with and without management present, to discuss the scope and results of their audits including internal control, auditing and financial reporting matters.

The financial statements and internal control over financial reporting have been audited by Ernst & Young LLP, an independent registered public accounting firm. Ernst & Young's reports with respect to fairness of presentation of the statements, and the effectiveness of internal control over financial reporting are included herein.



Edward J. Ludwig
Chairman, President and
Chief Executive Officer



John R. Considine
Senior Executive Vice President
and Chief Financial Officer



William A. Tozzi
Vice President—
Finance

Report of Independent Registered Public Accounting Firm

Becton, Dickinson and Company

To the Shareholders and Board of Directors of
Becton, Dickinson and Company


We have audited the accompanying consolidated balance sheets of Becton, Dickinson and Company as of September 30, 2007 and 2006, and the related consolidated statements of income, comprehensive income, and cash flows for each of the three years in the period ended September 30, 2007. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Becton, Dickinson and Company at September 30, 2007 and 2006, and the consolidated results of its operations and its cash flows for each of the three years in the period ended September 30, 2007, in conformity with U.S. generally accepted accounting principles.

As discussed in Notes 2 and 5 to the consolidated financial statements, the Company adopted Financial Accounting Standard No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106 and 132(R)" on September 30, 2007.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Becton, Dickinson and Company's internal control over financial reporting as of September 30, 2007, based on criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated November 16, 2007 expressed an unqualified opinion thereon.



ERNST & YOUNG LLP
New York, New York
November 16, 2007

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of
Becton, Dickinson and Company

We have audited Becton, Dickinson and Company's internal control over financial reporting as of September 30, 2007, based on criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Becton, Dickinson and Company's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.


A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Becton, Dickinson and Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2007, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Becton, Dickinson and Company as of September 30, 2007 and 2006, and the related consolidated statements of income, comprehensive income, and cash flows for each of the three years in the period ended September 30, 2007 of Becton, Dickinson and Company, and our report dated November 16, 2007 expressed an unqualified opinion thereon.

The logo for Ernst & Young LLP, featuring the company name in a stylized, handwritten-style script.

ERNST & YOUNG LLP
New York, New York
November 16, 2007

Consolidated Statements of Income

Years Ended September 30

Thousands of dollars, except per share amounts

	2007	2006	2005
Operations			
Revenues	\$6,359,708	\$5,738,017	\$5,340,833
Cost of products sold	3,071,921	2,793,265	2,622,427
Selling and administrative expense	1,602,404	1,448,166	1,386,897
Research and development expense	360,050	301,872	267,664
Acquired in-process research and development	122,133	53,300	—
Total Operating Costs and Expenses	5,156,508	4,596,603	4,276,988
Operating Income	1,203,200	1,141,414	1,063,845
Interest expense	(46,420)	(66,046)	(55,673)
Interest income	46,221	59,296	36,421
Other income (expense), net	944	(8,762)	(7,064)
Income From Continuing Operations			
Before Income Taxes	1,203,945	1,125,902	1,037,529
Income tax provision	347,778	310,792	325,009
Income from Continuing Operations	856,167	815,110	712,520
Income (loss) from Discontinued Operations			
Net of income tax provision (benefit) of \$15,242, \$(32,823) and \$(26,877)	33,866	(62,830)	9,743
Net Income	\$ 890,033	\$ 752,280	\$ 722,263
Basic Earnings per Share			
Income from Continuing Operations	\$ 3.50	\$ 3.30	\$ 2.83
Income (loss) from Discontinued Operations	\$ 0.14	\$ (0.25)	\$ 0.04
Basic Earnings per Share ^(A)	\$ 3.63	\$ 3.04	\$ 2.87
Diluted Earnings per Share			
Income from Continuing Operations	\$ 3.36	\$ 3.18	\$ 2.73
Income (loss) from Discontinued Operations	\$ 0.13	\$ (0.24)	\$ 0.04
Diluted Earnings per Share ^(A)	\$ 3.49	\$ 2.93	\$ 2.77

(A) Total per share amounts may not add due to rounding.

See notes to consolidated financial statements

Consolidated Statements of Comprehensive Income

Years Ended September 30

Thousands of dollars

	2007	2006	2005
Net Income	\$ 890,033	\$752,280	\$722,263
Other Comprehensive Income (Loss), Net of Tax			
Foreign currency translation adjustments	250,411	77,396	(17,742)
Minimum pension liability adjustment	3,159	77,086	4,494
Unrealized (loss) gain on investments, net of amounts recognized	(10,643)	1,212	(1,112)
Unrealized loss on cash flow hedges, net of amounts realized	(2,596)	(1,307)	(135)
Other Comprehensive Income (Loss), Net of Tax	240,331	154,387	(14,495)
Comprehensive Income	\$1,130,364	\$906,667	\$707,768

See notes to consolidated financial statements

Consolidated Balance Sheets

September 30

Thousands of dollars, except per share amounts and numbers of shares

	2007	2006
Assets		
Current Assets		
Cash and equivalents	\$ 511,482	\$1,000,289
Short-term investments	158,040	106,386
Trade receivables, net	1,083,152	885,748
Inventories	1,051,959	875,738
Prepaid expenses, deferred taxes and other	325,933	317,092
Total Current Assets	3,130,566	3,185,253
Property, Plant and Equipment, Net	2,497,338	2,133,548
Goodwill	621,414	565,146
Core and Developed Technology, Net	374,779	244,811
Other Intangibles, Net	95,938	91,501
Capitalized Software, Net	142,738	189,355
Other	466,592	414,911
Total Assets	\$ 7,329,365	\$6,824,525
Liabilities		
Current Liabilities		
Short-term debt	\$ 207,634	\$ 427,218
Accounts payable	266,993	243,602
Accrued expenses	481,429	490,425
Salaries, wages and related items	435,854	380,478
Income taxes	86,899	34,606
Total Current Liabilities	1,478,809	1,576,329
Long-Term Debt	955,713	956,971
Long-Term Employee Benefit Obligations	444,874	270,495
Deferred Income Taxes and Other	88,012	184,526
Commitments and Contingencies	—	—
Shareholders' Equity		
Common stock—\$1 par value: authorized—640,000,000 shares; issued—332,662,160 shares in 2007 and 2006	332,662	332,662
Capital in excess of par value	1,125,368	873,535
Retained earnings	5,995,787	5,345,697
Deferred compensation	12,205	11,134
Common stock in treasury—at cost—88,825,066 shares in 2007 and 87,194,060 shares in 2006	(3,105,893)	(2,698,016)
Accumulated other comprehensive income (loss)	1,828	(28,808)
Total Shareholders' Equity	4,361,957	3,836,204
Total Liabilities and Shareholders' Equity	\$ 7,329,365	\$6,824,525

See notes to consolidated financial statements

Consolidated Statements of Cash Flows

Years Ended September 30

Thousands of dollars

	2007	2006	2005
Operating Activities			
Net income	\$ 890,033	\$ 752,280	\$ 722,263
(Income) loss from discontinued operations, net	(33,866)	62,830	(9,743)
Income from continuing operations, net	856,167	815,110	712,520
Adjustments to income from continuing operations to derive net cash provided by continuing operating activities, net of amounts acquired:			
Depreciation and amortization	441,341	402,332	382,669
Share-based compensation	107,706	108,613	70,199
Deferred income taxes	(115,489)	(108,285)	63,769
Acquired in-process research and development	122,133	53,300	—
Change in operating assets and liabilities:			
Trade receivables, net	(117,048)	(19,977)	(34,332)
Inventories	(126,863)	(99,505)	(57,371)
Prepaid expenses, deferred taxes and other	(24,965)	(122,496)	(897)
Accounts payable, income taxes and other liabilities	102,996	100,636	107,929
Pension obligation	(22,119)	(64,971)	(58,842)
Other, net	12,189	39,416	35,105
Net Cash Provided by Continuing Operating Activities	1,236,048	1,104,173	1,220,749
Investing Activities			
Capital expenditures	(556,394)	(457,067)	(315,840)
Capitalized software	(22,334)	(22,454)	(18,922)
Change in short-term investments	(30,167)	(18,633)	(43,775)
Purchases of long-term investments	(3,881)	(9,672)	(1,171)
Acquisitions of businesses, net of cash acquired	(339,528)	(231,464)	—
Proceeds from discontinued operations	19,971	—	62,051
Other, net	(85,922)	(44,656)	(62,566)
Net Cash Used for Continuing Investing Activities	(1,018,255)	(783,946)	(380,223)
Financing Activities			
Change in short-term debt	(121,102)	121,563	157,103
Payments of debt	(100,790)	(828)	(104,522)
Repurchase of common stock	(450,124)	(448,882)	(549,999)
Issuance of common stock	130,679	147,796	123,494
Excess tax benefit from payments under share-based compensation plans	55,118	50,609	40,594
Dividends paid	(239,810)	(212,431)	(182,236)
Net Cash Used for Continuing Financing Activities	(726,029)	(342,173)	(515,566)
Discontinued Operations:			
Net cash provided by (used for) operating activities	4,388	(27,773)	(3,954)
Net cash used for investing activities	—	(2,580)	(528)
Net cash used for financing activities	—	—	(15)
Net Cash Provided by (Used for) Discontinued Operations	4,388	(30,353)	(4,497)
Effect of exchange rate changes on cash and equivalents	15,041	9,698	3,049
Net (Decrease) Increase in Cash and Equivalents	(488,807)	(42,601)	323,512
Opening Cash and Equivalents	1,000,289	1,042,890	719,378
Closing Cash and Equivalents	\$ 511,482	\$1,000,289	\$1,042,890

See notes to consolidated financial statements

Notes to Consolidated Financial Statements

Becton, Dickinson and Company

Thousands of dollars, except per share amounts and numbers of shares

1 Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Becton, Dickinson and Company and its majority-owned subsidiaries (the “Company”) after the elimination of inter-company transactions. The Company has no material interests in variable interest entities and none that require consolidation.

Cash Equivalents

Cash equivalents consist of all highly liquid investments with a maturity of three months or less when purchased.

Short-Term Investments

Short-term investments consist of certificates of deposit and repurchase agreements of government securities with maturities of less than one year when purchased.

Inventories

Inventories are stated at the lower of first-in, first-out cost or market.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four to 10 years for machinery and equipment and two to 17 years for leasehold improvements. Depreciation and amortization expense was \$280,357, \$262,956 and \$242,063 in fiscal 2007, 2006 and 2005, respectively.

Goodwill and Other Intangible Assets

Goodwill is reviewed annually for impairment in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and Other Intangible Assets”. In reviewing goodwill for impairment, potential impairment is identified by comparing the fair value of a reporting unit, estimated using an income approach, with its carrying value. Core and developed technology is amortized over periods ranging from 15 to 20 years, using the straight-line method. Both goodwill and core and developed technology arise from acquisitions.

Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from two to 40 years, using the straight-line method. These intangibles, including core and developed technology, are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows in accordance with SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”. To the extent carrying value exceeds the undiscounted cash flows, an impairment loss is recognized in operating results based upon the excess of the carrying value over fair value. Other intangibles also include certain trademarks that are considered to have indefinite lives, as they are expected to generate cash flows indefinitely, and are reviewed annually for impairment.

Capitalized Software

Capitalized software, including costs for software developed or obtained for internal use is stated at cost, less accumulated amortization. Amortization expense is principally provided on the straight-line basis over estimated useful lives, which do not exceed 10 years. Amortization expense was \$66,386, \$66,037 and \$71,416 for 2007, 2006 and 2005, respectively.

Foreign Currency Translation

Generally, the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss).

Revenue Recognition

Revenue from product sales is recognized when title and risk of loss pass to the customer. For the sale of certain instruments in the Biosciences segment, revenue is recognized upon completion of installation at the customer’s site. Based upon the terms of other sales arrangements, the Biosciences segment recognizes revenue in accordance with Emerging Issues Task Force No. 00-21, “Revenue Arrangements with Multiple Deliverables”. These sales arrangements have multiple deliverables and, as such, are divided into separate units of accounting. Revenue and cost of products sold are recognized at the completion of each deliverable based on the relative fair values of items delivered.

The Company's domestic businesses sell products primarily to distributors who resell the products to end-user customers. Rebates are provided to distributors that sell to end-user customers at prices determined under a contract between the Company and the end-user customer. Provisions for rebates, as well as sales discounts and returns, are accounted for as a reduction of revenues when revenue is recognized.

Shipping and Handling Costs

Shipping and handling costs are included in Selling and administrative expense. Shipping expense was \$243,263, \$219,788 and \$216,239 in 2007, 2006 and 2005, respectively.

Derivative Financial Instruments

In accordance with SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities," as amended, all derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met.

Derivative financial instruments are utilized by the Company in the management of its foreign currency and interest rate exposures. The Company hedges its foreign currency exposures by entering into offsetting forward exchange contracts and currency options when it deems appropriate. The Company utilizes interest rate swaps and forward rate agreements to manage its exposure to fluctuating interest rates. The Company does not use derivative financial instruments for trading or speculative purposes.

Any deferred gains or losses associated with derivative instruments, which on infrequent occasions may be terminated prior to maturity, are recognized in income in the period in which the underlying hedged transaction is recognized. In the event a designated hedged item is sold, extinguished or matures prior to the termination of the related derivative instrument, such instrument would be closed and the resultant gain or loss would be recognized in income.

Income Taxes

United States income taxes are not provided on undistributed earnings of foreign subsidiaries where such undistributed earnings are indefinitely reinvested outside the United States. Deferred taxes are provided for earnings of foreign subsidiaries when those earnings are not considered indefinitely reinvested. Income taxes are provided and tax credits are recognized based on tax laws enacted at the dates of the financial statements.

The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.

Earnings per Share

Basic earnings per share are computed based on the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.

Share-Based Compensation

The Company accounts for all share-based compensation under SFAS No. 123 (revised 2004)—"Share-Based Payment" ("SFAS No. 123(R)"). This statement requires the recognition of the fair value of share-based compensation in net income. Compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

2 Accounting Changes

In September 2006, the Financial Accounting Standards Board (the “FASB”) issued SFAS No. 158 “Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106 and 132(R)” (“SFAS No. 158”). SFAS No. 158 requires the Company to recognize the overfunded or underfunded status of a defined benefit postretirement plan as an asset or liability in its Consolidated Balance Sheet and to recognize changes in the funded status in the year in which the changes occur through comprehensive income. SFAS No. 158 also requires the funded status of a plan to be measured as of the balance sheet date and provides for additional disclosure requirements. The Company adopted SFAS No. 158 on September 30, 2007. SFAS No. 158 will not change the measurement date of the Company’s plans as the plans are measured at its fiscal year-end. See Note 5 regarding the Company’s adoption of SFAS No. 158.

In March 2005, the FASB issued Interpretation No. 47 “Accounting for Conditional Asset Retirement Obligations” (“FIN 47”). FIN 47 clarifies that the term “conditional asset retirement obligation” as used in SFAS No. 143, “Accounting for Asset Retirement Obligations” refers to a legal obligation to perform an asset retirement activity in which the timing and/or method of settlement are conditional on a future event that may or may not be within the control of the Company. Accordingly, the Company is required to recognize a liability for the fair value of a conditional asset retirement obligation if the fair value can be reasonably estimated. The Company adopted this interpretation in the fourth quarter of 2006. The adoption of FIN 47 did not have a material impact on BD’s consolidated financial statements.

Adoption of New Accounting Standard

In July 2006, the FASB issued Interpretation No. 48 “Accounting for Uncertainty in Income Taxes” (“FIN 48”). FIN 48 prescribes guidance for recognition, measurement, and disclosure of uncertain tax positions recognized in financial statements in accordance with SFAS No. 109 “Accounting for Income Taxes”. This interpretation will be applied to all tax positions upon its initial adoption.

The Company adopted this interpretation on October 1, 2007 and the cumulative effect of applying this interpretation will be reported as an adjustment to the opening balance of retained earnings for such fiscal year. Although the Company is still evaluating the potential impact of FIN 48, the decrease to opening retained earnings as of October 1, 2007, with a corresponding increase to the appropriate tax liability accounts, is not expected to exceed \$15 million.

3 Acquisitions and Divestitures

TriPath

On December 20, 2006, the Company acquired the outstanding shares (approximately 93.8%) of TriPath Imaging, Inc. (“TriPath”) which it did not previously own. TriPath develops, manufactures, markets and sells innovative solutions to improve the clinical management of cancer, including detection, diagnosis, staging and treatment. The acquisition advances the Company’s position in cancer diagnostics. The acquisition was accounted for under the purchase method of accounting and the results of operations of TriPath were included in the Company’s results as of the acquisition date. Pro forma information was not provided as the acquisition did not have a material effect on the Company’s consolidated results. The purchase price was \$361,883 in cash, including transaction costs and other consideration. The purchase price was allocated based upon the fair values of the assets and liabilities acquired. The allocation of the purchase price resulted in deferred tax assets of \$74,221 primarily consisting of net operating loss carry-forwards and credits; core and developed technology of \$135,097; deferred tax liabilities of \$52,662 primarily associated with other intangible assets; and other net assets of \$59,024 consisting primarily of cash and trade receivables. Core and developed technology will be amortized on a straight-line basis over its estimated useful life of

approximately 15 years. The excess of the purchase price over the fair value of the assets acquired of \$31,464 was recorded as goodwill. The primary items that generated goodwill are the value of expanded product opportunities in oncology that are aligned with and complement ongoing research programs at the Company. The goodwill was allocated to the Diagnostics segment and is not deductible for tax purposes. As a result of settling a preacquisition legal contingency in the fourth quarter, the Company recorded an increase to other net assets and a decrease to goodwill of \$7,167, which was reflected in the above allocation of the purchase price.

In connection with the acquisition, the Company also incurred a non-deductible charge of \$114,739 for acquired in-process research and development. This charge, based on fair value, is associated with three projects: molecular Pap test, breast staging, and ovarian cancer detection. These projects had not yet reached technological feasibility and did not have alternative future use at the acquisition date. The portion of the charge allocated to each of these projects was \$75,992, \$18,764 and \$19,983, respectively.

The molecular Pap test uses proprietary molecular biomarkers and reagents that are intended to allow for the primary screening of cervical cancer. The diagnostic assay is being developed to test slides prepared using TriPath's SurePath® liquid-based Pap test and to permit concurrent evaluation of morphologic features and measurement of the over-expression of molecular biomarkers that are associated with biopsy-proven moderate to severe cervical disease and cancer. Clinical trials have been initiated for this project.

The breast staging project uses proprietary molecular biomarkers and reagents that are intended to predict the risk of disease recurrence and to aid in treatment selection in patients with early stage breast cancer. The diagnostic assay is being developed for use with commercially available detection kits and staining platforms and will utilize TriPath's interactive histology imaging system to quantify biomarker over-expression in tissue samples collected at the time of initial diagnosis of breast cancer. Clinical trials have been initiated for this project.

The ovarian cancer detection project is intended to allow for serum-based screening and monitoring assays for ovarian cancer based upon the detection of multiple biomarkers using a proprietary panel of biomarkers and assay algorithms. In addition, multiplex testing platforms are being evaluated to allow for the simultaneous testing of multiple markers from a small volume of serum. The detection assays being developed will utilize certain technologies from the Biosciences segment. Clinical trials have not been initiated for this project.

The fair values of these projects were determined based upon the present value of projected cash flows utilizing an income approach reflecting the appropriate risk-adjusted discount rate based on the applicable technological and commercial risk of each project. These cash flows also took into account the income and expenses associated with the further development and commercialization of the underlying products. The range of discount rates assigned to the projects was 22 to 30 percent and gave consideration to the underlying risk relative to the developed technology, the overall commercial and technical risk, and the probabilities of success for each of the projects. The ongoing activity associated with each of these projects is not expected to be material to the Company's research and development expense.

Other

On May 4, 2007, the Company acquired all of the outstanding shares of Plasso Technology, Ltd. ("Plasso"), a privately-held company that is developing the next generation of surface-critical research tools utilizing functional coating technology for applications in glycomics and cell culture, for \$10,425 in cash including transaction costs. In connection with the acquisition, the Company incurred a non-deductible charge of \$7,394 for acquired in-process research and development associated with Plasso's technology, for which, at the acquisition date, technological feasibility had not been established and no alternative future use existed. Because Plasso was a development stage company that had not commenced its planned principal operations, the transaction was accounted for as an acquisition of assets rather than as a business combination and, therefore, goodwill was not recorded.

GeneOhm

On February 14, 2006, the Company acquired all the outstanding stock of GeneOhm Sciences, Inc. ("GeneOhm"), a company that develops molecular diagnostic testing for the rapid detection of bacterial organisms, including those known to cause healthcare-associated infections. The acquisition provides the Company with expanded entry into the emerging field of healthcare-associated infections. The acquisition was accounted for under the purchase method of accounting and the results of operations of GeneOhm were included in the Company's results as of the acquisition date. Pro forma information was not provided as the acquisition did not have a material effect on the Company's consolidated results. The purchase price consisted of an up-front cash payment of \$232,542, including transaction costs, and the purchase contract provides for additional contingent payments of up to \$25,000, based on future events occurring on or before December 31, 2007. The purchase price was allocated based upon the fair values of the assets and liabilities acquired. The allocation of the purchase price resulted in deferred tax assets of \$34,346 consisting of net operating loss carryforwards and credits; other intangible assets, primarily core and developed technology, of \$92,300; deferred tax liabilities of \$31,400 associated with other intangible assets, and other net assets of \$3,587. Core and developed technology will be amortized on a straight-line basis over its estimated useful life of approximately 15 years. The excess of the purchase price over the fair value of the assets acquired of \$80,409 was recorded as goodwill. The primary items that generated goodwill are the value of synergies in microbiology research and the expansion of product offerings in molecular diagnostics. The goodwill was allocated to the Diagnostics segment and is not deductible for tax purposes. In connection with the acquisition, the Company also incurred a non-deductible charge of \$53,300 for acquired in-process research and development. This charge, based on fair value, is associated with several products that have not reached technological feasibility and do not have alternative future use at the acquisition date. The fair value of each product was determined based upon the present value of projected cash flows utilizing an income approach reflecting the appropriate risk-adjusted discount rate based on the applicable technological and commercial risk of each product. These cash flows took into account the income and expenses associated with the further development and commercialization of the underlying products. The ongoing activity associated with each of these products is not material to the Company's research and development expense.

BGM

On September 28, 2006, the Company announced a plan to exit the blood glucose monitoring ("BGM") market. In accordance with the plan, distribution of the *BD Logic* Blood Glucose Monitor was immediately discontinued. BD will continue to distribute test strips for its customers through December 2007. The decision to exit the BGM market was made following an evaluation of the future outlook for the product line. The Company recorded a pre-tax charge of \$63,414 in 2006 in connection with its decision to exit the BGM product line. This charge consisted of \$5,352 related to estimated customer sales returns, \$31,602 related to the write-off of inventory and related purchase commitments, \$14,052 related to long-lived asset write-downs, and \$12,408 related to severance and other exit costs. During the fourth quarter of 2007, the Company reversed \$8,781 of this charge to reinstate certain long-lived assets to reflect the use of these assets. At September 30, 2006, an accrual of \$32,408, which primarily consisted of inventory-related purchase commitments and severance, was reported in current liabilities. At September 30, 2007, the accrual was substantially utilized, after reflecting the reversal of \$5,365 of these costs during 2007.

During the first quarter of 2007, the Company received an unsolicited offer for the purchase of the BGM product line. On December 11, 2006, the Company sold the product line for \$19,971 and recognized a pre-tax gain on sale of \$15,226. During the second quarter of 2007, the Company recognized adjustments, thereby increasing the gain on sale by \$6,093. These adjustments constitute revisions to estimated sales return accruals, primarily related to obligations that ceased to exist in the second quarter pursuant to the sale terms. During 2007, adjustments of \$3,226 were made to reduce other accruals related to obligations that remained with the Company upon divestiture of the product line. Additionally, the Company received a payment of \$4,675, which represented the resolution of a contingency with a former supplier. Following the sale, the Company's prior period Consolidated Statements of Income and Cash Flows and related disclosures have been restated to separately present the results of the BGM product line as discontinued operations. The September 30, 2006 Consolidated Balance Sheet has not been restated.

Other

In August 2005, the Company completed the sale of the Clontech unit of the Biosciences segment for \$62,100 and recognized a gain on sale of \$13,336 (\$28,533 after taxes). Clontech's results of operations were reported as discontinued operations for all periods presented in the accompanying Consolidated Statements of Income and Cash Flows.

Results of discontinued operations for the years ended September 30 were as follows:

	2007	2006	2005 ^(B)
Revenues	\$ 33,086	\$ 96,811	\$123,518
Income (loss) from discontinued operations before income taxes	49,108	(95,653) ^(A)	(17,134)
Income tax (provision) benefit	(15,242)	32,823	26,877
Income (loss) from discontinued operations, net	\$ 33,866	\$(62,830) ^(A)	\$ 9,743

(A) Includes post-closing charges of \$4,708 (\$3,311 after taxes) related to the divestiture of Clontech.

(B) Includes revenues of \$49,670 and income before taxes of \$15,541 (\$29,980 after taxes) related to the operations of Clontech. The effective tax rate benefit of 92.9% reflected the consummation of the sale of Clontech as a sale of stock, which was previously assumed to be an asset sale. The Company recognized a benefit from the write-off of deferred tax liabilities associated with basis adjustments.

4 Other Intangible Assets

Other intangible assets at September 30 consisted of:

	2007		2006	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Amortized intangible assets				
Core and developed technology	\$548,995	\$174,216	\$377,633	\$132,822
Patents, trademarks, and other	289,920	203,037	337,176	254,717
	\$838,915	\$377,253	\$714,809	\$387,539
Unamortized intangible assets				
Trademarks	\$ 9,055		\$ 9,042	

Intangible amortization expense was \$46,607, \$34,843 and \$29,529 in 2007, 2006 and 2005, respectively. The estimated aggregate amortization expense for the fiscal years ending September 30, 2008 to 2012 are as follows: 2008-\$49,100; 2009-\$46,900; 2010-\$45,200; 2011-\$43,700; 2012-\$40,600.

5 Benefit Plans

The Company has defined benefit pension plans covering substantially all of its employees in the United States and certain foreign locations. The Company also provides certain postretirement healthcare and life insurance benefits to qualifying domestic retirees. Postretirement healthcare and life insurance benefit plans in foreign countries are not material. The measurement date used for the Company's employee benefit plans is September 30.

During 2007, the Company redesigned its U.S. pension plans to provide for a cash benefit formula by offering a one-time, irrevocable election to existing employees to change to this provision and mandating all new employees hired after April 1, 2007 to participate in the new formula. The Company also amended its other postretirement benefits plan to provide that new hires, as of April 1, 2007 or later, will no longer be eligible for company subsidized benefits. These amendments did not have a material impact on the net pension and postretirement cost of the Company.

Net pension and other postretirement cost for the years ended September 30 included the following components:

	Pension Plans			Other Postretirement Benefits		
	2007	2006	2005	2007	2006	2005
Service cost	\$ 69,869	\$ 74,111	\$ 61,836	\$ 4,386	\$ 4,164	\$ 3,657
Interest cost	75,728	71,997	66,837	14,608	14,873	15,321
Expected return on plan assets	(88,527)	(80,063)	(59,372)	—	—	—
Amortization of prior service cost	348	309	211	(6,233)	(6,233)	(6,233)
Amortization of loss	17,507	27,932	22,951	5,795	7,127	6,164
Amortization of net obligation	(92)	(70)	134	—	—	—
	\$ 74,833	\$ 94,216	\$ 92,597	\$18,556	\$19,931	\$18,909

Net pension cost attributable to foreign plans included in the preceding table was \$21,156, \$18,639 and \$16,772 in 2007, 2006 and 2005, respectively.

Effective September 30, 2007, the Company adopted the recognition and disclosure provisions of SFAS No. 158, which requires the Company to recognize on a prospective basis the funded status of its pension and other postretirement benefit plans in the Consolidated Balance Sheet with a corresponding adjustment to Accumulated other comprehensive income (loss). The Company also recognized the funded status of its postemployment benefit plans in connection with the adoption of SFAS No. 158. The minimum pension liability, previously included in Accumulated other comprehensive income (loss), and the related intangible asset were derecognized upon the adoption of SFAS No. 158.

The effects of applying SFAS No. 158 at September 30, 2007 were as follows:

	Before Application of SFAS No. 158	SFAS No. 158 Adjustments	After Application of SFAS No. 158
Prepaid expenses, deferred			
taxes and other	\$ 326,119	\$ (186)	\$ 325,933
Other Intangibles, Net	96,391	(453)	95,938
Other	502,428	(35,836)	466,592
Salaries, wages and related items	(435,857)	3	(435,854)
Long-Term Employee			
Benefit Obligations	(268,128)	(176,746)	(444,874)
Deferred Income Taxes and Other	(91,535)	3,523	(88,012)
Accumulated other comprehensive			
income	(211,523)	209,695	(1,828)

The change in benefit obligation, change in fair value of plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows:

	Pension Plans		Other Postretirement Benefits	
	2007	2006	2007	2006
Change in benefit obligation:				
Beginning obligation	\$1,384,667	\$1,413,092	\$ 255,726	\$ 281,197
Service cost	69,869	74,111	4,386	4,164
Interest cost	75,728	71,997	14,608	14,873
Plan amendments	(16,586)	86	—	—
Benefits paid	(97,671)	(75,207)	(25,411)	(22,734)
Actuarial gain	(63,519)	(117,307)	(11,818)	(24,345)
Other, includes translation	41,942	17,895	8,480	2,571
Benefit obligation at September 30	\$1,394,430	\$1,384,667	\$ 245,971	\$ 255,726
Change in fair value of plan assets:				
Beginning fair value	\$1,124,565	\$ 933,920	\$ —	\$ —
Actual return on plan assets	138,446	91,569	—	—
Employer contribution	96,952	160,340	—	—
Benefits paid	(97,671)	(75,207)	—	—
Other, includes translation	33,877	13,943	—	—
Plan assets at September 30	\$1,296,169	\$1,124,565	\$ —	\$ —
Funded status at September 30:				
Unfunded benefit obligation	\$ (98,261)	\$ (260,102)	\$ (245,971)	\$ (255,726)
Unrecognized net transition obligation	—	(1,012)	—	—
Unrecognized prior service cost (credit)	—	6,193	—	(12,920)
Unrecognized net actuarial loss	—	356,968	—	77,392
Net amount recognized	\$ (98,261)	\$ 102,047	\$ (245,971)	\$ (191,254)
Amounts recognized in the Consolidated Balance Sheets at September 30:				
Other Intangibles, Net	\$ —	\$ 2,345	\$ —	\$ —
Other	32,710	148,129	—	—
Salaries, wages and related items	(2,668)	—	(20,067)	—
Long-Term Employee Benefit Obligations	(128,303)	(67,996)	(225,904)	(191,254)
Accumulated other comprehensive income (loss) before income taxes	—	19,569	—	—
Net amount recognized	\$ (98,261)	\$ 102,047	\$ (245,971)	\$ (191,254)
Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30:				
Net transition obligation	\$ (1,156)		\$ —	
Prior service credit	(10,086)		(6,688)	
Net actuarial loss	238,144		62,194	
Net amount recognized	\$ 226,902		\$ 55,506	

Foreign pension plan assets at fair value included in the preceding table were \$359,291 and \$299,047 at September 30, 2007 and 2006, respectively. The foreign pension plan projected benefit obligations were \$430,265 and \$382,584 at September 30, 2007 and 2006, respectively.

The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for the pension plans with accumulated benefit obligations in excess of plan assets were \$96,723, \$76,398 and \$14,685, respectively as of September 30, 2007, and \$126,545, \$100,473 and \$41,576, respectively as of September 30, 2006.

The estimated net actuarial loss and prior service credit for pension benefits that will be amortized from Accumulated other comprehensive loss into net pension costs over the next fiscal year are expected to be \$7,825 and \$(1,117) million, respectively. The estimated net actuarial loss and prior service credit for other postretirement benefits that will be amortized from Accumulated other comprehensive income (loss) into net other postretirement costs over the next fiscal year are expected to be \$3,949 and \$(6,233) million, respectively.

The weighted average assumptions used in determining pension plan information were as follows:

	2007	2006	2005
Net Cost			
Discount rate:			
U.S. plans ^(A)	5.95%	5.50%	6.00%
Foreign plans	4.65	4.19	4.95
Expected return on plan assets:			
U.S. plans	8.00	8.00	8.00
Foreign plans	6.42	6.02	6.60
Rate of compensation increase:			
U.S. plans ^(A)	4.50	4.25	4.25
Foreign plans	3.08	2.92	2.98
Benefit Obligation			
Discount rate:			
U.S. plans ^(A)	6.35	5.95	5.50
Foreign plans	5.32	4.65	4.19
Rate of compensation increase:			
U.S. plans ^(A)	4.50	4.50	4.25
Foreign plans	3.45	3.08	2.92

(A) Also used to determine other postretirement and postemployment benefit plan information.

At September 30, 2007 the assumed healthcare trend rates were 9% pre and post age 65, gradually decreasing to an ultimate rate of 5% beginning in 2012. At September 30, 2006 the corresponding assumed healthcare trend rates were 10% pre and post age 65, gradually decreasing to an ultimate rate of 5% beginning in 2012. A one percentage point increase in assumed healthcare cost trend rates in each year would increase the accumulated postretirement benefit obligation as of September 30, 2007 by \$11,165 and the aggregate of the service cost and interest cost components of 2007 annual expense by \$759. A one percentage point decrease in the assumed healthcare cost trend rates in each year would decrease the accumulated postretirement benefit obligation as of September 30, 2007 by \$9,977 and the aggregate of the 2007 service cost and interest cost by \$677.

Expected Funding

The Company's funding policy for its defined benefit pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that may be appropriate considering the funded status of the plans, tax consequences, the cash flow generated by the Company and other factors. While the Company will not be required to fund any of its pension plans in 2008, the Company made a discretionary contribution to a certain foreign pension plan in October 2007 of \$22,900.

Expected benefit payments are as follows:

	Pension Plans	Other Postretirement Benefits
2008	\$ 81,738	\$ 20,067
2009	70,735	20,378
2010	75,948	20,798
2011	81,612	20,907
2012	89,059	20,757
2013-2017	522,634	100,137

Expected receipts of the subsidy under the Medicare Prescription Drug Improvement and Modernization Act of 2003, which are not reflected in the expected other postretirement benefit payments included in the preceding table, are as follows: 2008, \$2,059; 2009, \$2,190; 2010, \$2,280; 2011, \$2,362; 2012, \$2,417; 2013-2017, \$12,174.

The Company's asset allocations for its defined benefit pension plans at September 30 were as follows:

	2007	2006
Equity securities	64.5%	64.4%
Debt securities	33.1	33.0
Other	2.4	2.6
	100.0%	100.0%

Investment Strategy

The Company's investment objective is to achieve superior returns on plan assets, subject to a prudent level of portfolio risk, for the purpose of enhancing the security of benefits for participants. The Company's investments include a broad range of equity and fixed-income securities. These investments are diversified in terms of domestic and international equity securities, short-term and long-term securities, growth and value styles, as well as small and large capitalization stocks. The Company's target allocation percentages are as follows: equity securities (58%–69%); fixed-income securities (31%–39%); and cash (0%–3%). Equity securities are held for their expected high return and excess return over inflation. Fixed-income securities are held for diversification relative to equities. The plans may also hold cash to meet liquidity requirements. Due to short-term fluctuations in market conditions, allocation percentages may temporarily deviate from these target allocation percentages before a rebalancing occurs. Investment risks and returns are measured and monitored on an on-going basis through annual liability measurements and quarterly investment portfolio reviews to determine whether the asset allocation targets continue to represent an appropriate balance of expected risk and reward.

The expected rate of return on plan assets is based upon expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, the Company considers historical and expected rates of return for the asset classes in which the plan's assets are invested, as well as current economic and capital market conditions.

Postemployment Benefits

The Company utilizes a service-based approach in applying SFAS No. 112, "Employers' Accounting for Postemployment Benefits—an amendment of FASB Statements No. 5 and 43," for most of its postemployment benefits. This approach recognizes that actuarial gains and losses may result from experience that differs from baseline assumptions.

Postemployment benefit costs for the years ended September 30 included the following components:

	2007	2006	2005
Service cost	\$10,449	\$10,148	\$8,975
Interest cost	5,116	4,946	4,438
Amortization of prior service cost	1,654	1,654	1,654
Amortization of loss	6,895	8,548	7,613
	\$24,114	\$25,296	\$22,680

The unfunded status of the postemployment benefit plans was \$101,514 at September 30, 2007 and these plans are not funded. The amounts recognized in Accumulated other comprehensive income (loss) before income taxes for the net actuarial loss was \$57,110 at September 30, 2007. The estimated net actuarial loss that will be amortized from the Accumulated other comprehensive income (loss) into postemployment benefit cost over the next fiscal year is \$6,845.

Savings Incentive Plan

The Company has a voluntary defined contribution plan ("Savings Incentive Plan") covering eligible employees in the United States. In connection with the redesign of the U.S. pension and postretirement benefit plans, effective July 1, 2007, the Company amended its Savings Incentive Plan increasing the amount of the Company matching contribution for eligible employees to 75% of employees' contributions, up to a maximum of 4.5% of each employee's eligible compensation. Prior to that date, the Company matched 50% of employees' contributions, up to a maximum of 3% of each employee's salary. The cost of the Savings Incentive Plan was \$21,878 in 2007, \$16,626 in 2006 and \$6,905 in 2005. The Company guarantees employees' contributions to the fixed income fund of the Savings Incentive Plan, which consists of diversified money market instruments. The amount guaranteed was \$144,772 at September 30, 2007.

6 Income Taxes

The provision for income taxes from continuing operations for the years ended September 30 consisted of:

	2007	2006	2005
Current:			
Federal	\$ 307,072	\$ 281,784	\$130,657
State and local, including Puerto Rico	21,669	12,004	5,169
Foreign	134,526	125,289	125,414
	463,267	419,077	261,240
Deferred:			
Domestic	(94,306)	(101,651)	76,540
Foreign	(21,183)	(6,634)	(12,771)
	(115,489)	(108,285)	63,769
	\$ 347,778	\$ 310,792	\$325,009

The components of Income From Continuing Operations Before Income Taxes for the years ended September 30 consisted of:

	2007	2006	2005
Domestic, including Puerto Rico	\$ 550,750	\$ 466,655	\$ 465,188
Foreign	653,195	659,247	572,341
	\$1,203,945	\$1,125,902	\$1,037,529

Deferred tax assets and liabilities are netted on the balance sheet by separate tax jurisdictions. At September 30, 2007 and 2006, net current deferred tax assets of \$168,305 and \$181,406, respectively, were included in Prepaid expenses, deferred taxes and other. Net non-current deferred tax assets of \$168,251 and \$32,582, respectively, were included in Other. Net current deferred tax liabilities of \$6,136 and \$2,184, respectively, were included in Current Liabilities—Income taxes. Net non-current deferred tax liabilities of \$37,121 and \$143,435, respectively, were included in Deferred Income Taxes and Other. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. At September 30, 2007, the cumulative amount of such undistributed earnings indefinitely reinvested outside the United States was \$1.6 billion. Determining the tax liability that would arise if these earnings were remitted is not practicable. Deferred taxes are provided for earnings outside the United States when those earnings are not considered indefinitely reinvested.

In October 2004, the American Jobs Creations Act of 2004 (the “AJCA”) was signed into law. The AJCA created a temporary incentive for U.S. multinationals to repatriate accumulated income earned outside the United States. As a result of the passage of the AJCA, the Company revisited its policy of indefinite reinvestment of foreign earnings and made a decision to repatriate approximately \$1.3 billion in 2006 pursuant to its approved repatriation plan. The Company recorded a charge of \$77,200 in 2005 attributable to the planned repatriation of these earnings. During 2006, the Company repatriated approximately \$1.3 billion in accordance with its planned repatriation under the AJCA. The actual tax charge associated with this repatriation was \$65,768.

Deferred income taxes at September 30 consisted of:

	2007		2006	
	Assets	Liabilities	Assets	Liabilities
Compensation and benefits	\$ 301,118	\$ —	\$146,432	\$ —
Property and equipment	—	190,979	—	144,365
Loss and credit carryforwards	193,981	—	111,388	—
Other	172,740	83,538	199,997	159,853
	667,839	274,517	457,817	304,218
Valuation allowance	(100,023)	—	(85,230)	—
	\$ 567,816	\$274,517	\$372,587	\$304,218

Valuation allowances have been established for capital loss carryforwards, state deferred tax assets, net of federal tax, related to net operating losses and credits and other deferred tax assets for which the Company has determined it is more likely than not that these benefits will not be realized. At September 30, 2007, the Company had deferred state tax assets for net state operating losses and credit carryforwards of \$49,641 for which a valuation allowance of \$33,191 has been established due to the uncertainty of generating sufficient taxable income in the state jurisdictions to utilize the deferred tax assets before they principally expire between 2008 and 2014. In 2007, a previously established valuation allowance of approximately \$19,700 related to state tax credit carryforwards was reversed and included in the state and local income tax line item in the following rate reconciliation table. The Company also has federal and state capital loss carryforward deferred tax assets of \$51,428 for which a full valuation allowance has been established due to the uncertainty of recognizing the benefit from these losses before they principally expire in 2010.

A reconciliation of the federal statutory tax rate to the Company's effective tax rate was as follows:

	2007	2006	2005
Federal statutory tax rate	35.0%	35.0%	35.0%
State and local income taxes, net of federal tax benefit	0.2	0.6	0.7
Effect of foreign and Puerto Rico earnings and foreign tax credits	(9.2)	(7.4)	(10.2)
Effect of Research, Domestic Production Activities, Extraterritorial Income tax benefits	(0.5)	(1.3)	(2.0)
Acquired in-process research and development	3.6	1.8	—
Repatriation of foreign earnings under the AJCA	—	(1.1)	7.7
Other, net	(0.2)	—	0.1
	28.9%	27.6%	31.3%

The approximate dollar and diluted earnings per share amounts of tax reductions related to tax holidays in various countries in which the Company does business were: 2007—\$80,300 and \$0.32; 2006—\$70,000 and \$0.27; and 2005—\$75,150 and \$0.29. The tax holidays expire at various dates through 2023.

The Company made income tax payments, net of refunds, of \$345,049 in 2007, \$398,808 in 2006 and \$183,867 in 2005.

7 Supplemental Financial Information

Other Income (Expense), Net

Other income (expense), net in 2007 was \$944, which primarily included income from license and other agreements of \$6,128, partially offset by net write downs of certain investments of \$(5,538) and foreign exchange losses (inclusive of hedging costs) of \$(4,191).

Other income (expense), net in 2006 was \$(8,762), which primarily included net write downs of certain investments of \$(11,046) and foreign exchange losses (inclusive of hedging costs) of \$(5,142), partially offset by income from license and other agreements of \$4,281.

Other income (expense), net in 2005 was \$(7,064), which primarily included foreign exchange losses (inclusive of hedging costs) of \$(3,976) and net write downs of certain investments of \$(3,519).

Trade Receivables, Net

Allowances for doubtful accounts and cash discounts netted against trade receivables were \$39,650 and \$38,256 at September 30, 2007 and 2006, respectively.

Inventories

Inventories at September 30 consisted of:

	2007	2006
Materials	\$ 142,484	\$121,598
Work in process	195,155	156,957
Finished products	714,320	597,183
	\$1,051,959	\$875,738

Property, Plant and Equipment, Net

Property, Plant and Equipment, Net at September 30 consisted of:

	2007	2006
Land	\$ 79,368	\$ 68,882
Buildings	1,597,356	1,361,614
Machinery, equipment and fixtures	3,596,781	3,239,397
Leasehold improvements	80,610	73,064
	5,354,115	4,742,957
Less accumulated depreciation and amortization	2,856,777	2,609,409
	\$2,497,338	\$2,133,548

8 Debt

Short-term debt at September 30 consisted of:

	2007	2006
Loans payable:		
Domestic	\$200,000	\$200,000
Foreign	6,768	126,121
Current portion of long-term debt	866	101,097
	\$207,634	\$427,218

Domestic loans payable consist of commercial paper. Foreign loans payable consist of short-term borrowings from financial institutions. The weighted average interest rates for Short-term debt were 5.2% and 4.6% at September 30, 2007 and 2006, respectively. During 2007, the Company amended its syndicated credit facility to increase the amount available from \$900 million to \$1 billion and extend the expiration date from August 2009 to December 2011.

During 2008, the facility was again amended, extending its expiration date to December 2012. This credit facility provides backup support for the commercial paper program and can also be used for other general corporate purposes. This credit facility includes a restrictive covenant that requires a minimum interest coverage ratio. There were no borrowings outstanding under the facility at September 30, 2007. In addition, the Company had short-term foreign lines of credit pursuant to informal arrangements of approximately \$175,000 at September 30, 2007, of which \$168,000 was unused.

Long-Term Debt at September 30 consisted of:

	2007	2006
Domestic notes due through 2013 (average year-end interest rate: 4.3%–2007; 4.2%–2006)	\$ 9,801	\$ 10,566
7.15% Notes due October 1, 2009	205,914	206,144
4.55% Notes due April 15, 2013	198,734	198,537
4.90% Notes due April 15, 2018	206,214	206,674
7.00% Debentures due August 1, 2027	168,000	168,000
6.70% Debentures due August 1, 2028	167,050	167,050
	\$955,713	\$956,971

Long-term debt balances as of September 30, 2007 and 2006 have been impacted by certain interest rate swaps that have been designated as fair value hedges, as discussed in Note 9.

The aggregate annual maturities of long-term debt during the fiscal years ending September 30, 2009 to 2012 are as follows: 2009–\$745; 2010–\$206,385; 2011–\$466; 2012–\$119.

The Company capitalizes interest costs as a component of the cost of construction in progress. A summary of interest costs for the years ended September 30 were as follows:

	2007	2006	2005
Charged to operations	\$46,420	\$66,046	\$55,673
Capitalized	27,528	19,955	14,770
	\$73,948	\$86,001	\$70,443

Interest paid, net of amounts capitalized, was \$50,730 in 2007, \$62,514 in 2006 and \$68,527 in 2005.

9 Financial Instruments

Foreign Exchange Derivatives

The Company uses foreign exchange forward contracts and currency options to reduce the effect of fluctuating foreign exchange rates on certain foreign currency denominated receivables and payables and third party product sales. Gains and losses on the derivatives are intended to offset gains and losses on the hedged transaction. The Company's foreign currency risk exposure is in Europe, Asia Pacific, Canada, Japan, and Latin America.

The Company hedges substantially all of its transactional foreign exchange exposures, primarily intercompany payables and receivables, through the use of forward contracts and currency options with maturities of less than 12 months. Gains or losses on these contracts are largely offset by gains and losses on the underlying hedged items. These foreign exchange contracts do not qualify for hedge accounting.

In addition, the Company enters into option and forward contracts to hedge certain forecasted sales that are denominated in foreign currencies. These contracts are designated as cash flow hedges and are effective as hedges of these revenues. These contracts are intended to reduce the risk that the Company's cash flows from certain third party transactions will be adversely affected by changes in foreign currency exchange rates. Changes in the effective portion of the fair value of these contracts are included in other comprehensive income until the hedged sales transactions are recognized in earnings. Once the hedged transaction occurs, the gain or loss on the contract is recognized from Accumulated other comprehensive income (loss) to revenues. The Company recorded hedge net gains, exclusive of hedging costs, of \$6,911 and \$8,242 and a net loss, exclusive of hedging costs, of \$1,876 to revenues in 2007, 2006 and 2005, respectively. Revenues in 2007, 2006 and 2005 are net of hedging costs of \$15,136, \$12,508 and \$17,286, respectively, related to the purchased option contracts. The Company records in Other income (expense), net, the premium or cost of the forward contracts, which is excluded from the assessment of hedge effectiveness. The net premium was \$562 in 2006 and the net cost was \$236 in 2005. All outstanding contracts that were designated as cash flow hedges as of September 30, 2007 will mature by September 30, 2008. At September 30, 2007 and 2006, Accumulated other comprehensive income (loss) included unrealized losses of \$4,994 and \$1,522, respectively, net of tax, relating to foreign exchange derivatives that have been designated as cash flow hedges.

Interest Rate Derivatives

The Company's policy is to manage interest cost using a mix of fixed and floating rate debt. The Company has entered into interest rate swaps in which it agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges. For fair value hedges, changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. For cash flow hedges, changes in the fair value of the interest rate swaps are offset by amounts recorded in other comprehensive income (loss). There was no ineffective portion to the hedges recognized in earnings during the period. If interest rate derivatives designated as cash flow hedges mature or are terminated, then the balance in other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The amount that will be reclassified and recorded in Interest expense within the next 12 months is \$1,760.

At September 30, 2007 and 2006, Accumulated other comprehensive income (loss) included an unrealized loss of \$11,397 and \$12,273, respectively, net of tax, relating to interest rate derivatives that have been designated as cash flow hedges.

Fair Value of Financial Instruments

Cash equivalents, short-term investments and short-term debt are carried at cost, which approximates fair value. Equity securities, where a readily determinable market value exists, are classified as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrecognized gains and losses reported in other comprehensive income (loss), net of taxes. Losses on available-for-sale securities are recognized when a loss is determined to be other than temporary or when realized.

The fair value of forward exchange contracts and currency options were estimated based on market prices, where available, or dealer quotes. The fair value of certain long-term debt is based on redemption value. The estimated fair values of the Company's financial instruments at September 30 were as follows:

	2007		2006	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Assets:				
Currency options ^(A)	\$ 3,982	\$ 3,982	\$ 12,471	\$ 12,471
Forward exchange contracts ^(A)	8,007	8,007	3,156	3,156
Interest rate swaps ^(A)	5,914	5,914	6,144	6,144
Equity securities	1,291	1,291	25,436 ^(B)	25,436 ^(B)
Liabilities:				
Forward exchange contracts ^(C)	8,968	8,968	2,878	2,878
Long-term debt	955,713	949,490	956,971	976,404

(A) Included in Prepaid expenses, deferred taxes and other.

(B) Included in Other non-current assets and primarily represents equity securities in TriPath, acquired on December 20, 2006.

(C) Included in Accrued Expenses.

Concentration of Credit Risk

Substantially all of the Company's trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company's customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions.

10 Shareholders' Equity

Changes in certain components of shareholders' equity were as follows:

	Common Stock Issued at Par Value	Capital in Excess of Par Value	Retained Earnings	Deferred Compensation	Treasury Stock	
					Shares	Amount
Balance at September 30, 2004	\$332,662	\$ 414,515	\$4,264,778	\$ 10,222	(83,327,295)	\$(1,816,756)
Net income			722,263			
Cash dividends:						
Common (\$.72 per share)			(181,189)			
Common stock issued for:						
Share-based compensation plans, net		124,220			4,638,097	44,839
Business acquisitions		206			4,565	45
Share-based compensation		70,199				
Common stock held in trusts, net				58	40,472	(58)
Repurchase of common stock					(9,711,800)	(549,999)
Conversion of ESOP preferred stock		6,706			3,378,028	24,436
Balance at September 30, 2005	\$332,662	\$ 615,846	\$4,805,852	\$ 10,280	(84,977,933)	\$(2,297,493)
Net income			752,280			
Cash dividends:						
Common (\$.86 per share)			(212,435)			
Common stock issued for:						
Share-based compensation plans, net		148,342			5,066,384	49,057
Business acquisitions		734			15,864	156
Share-based compensation		108,613				
Common stock held in trusts, net				854	(17,275)	(854)
Repurchase of common stock					(7,281,100)	(448,882)
Balance at September 30, 2006	\$332,662	\$ 873,535	\$5,345,697	\$ 11,134	(87,194,060)	\$(2,698,016)
Net income			890,033			
Cash dividends:						
Common (\$.98 per share)			(239,943)			
Common stock issued for:						
Share-based compensation plans, net		143,420			4,380,724	43,213
Business acquisitions		707			10,812	105
Share-based compensation		107,706				
Common stock held in trusts, net				1,071	(70,542)	(1,071)
Repurchase of common stock					(5,952,000)	(450,124)
Balance at September 30, 2007	\$332,662	\$1,125,368	\$5,995,787	\$ 12,205	(88,825,066)	\$(3,105,893)

Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company's employee salary and bonus deferral plan and directors' deferral plan. In December 2004, the remaining unallocated shares of ESOP preferred stock were converted to BD common stock and were fully utilized by April 2005.

11 Accumulated Other Comprehensive Income (Loss)

The components of Accumulated other comprehensive income (loss) were as follows:

	2007	2006
Foreign currency translation adjustments	\$ 237,394	\$(13,017)
Minimum pension liability adjustment	—	(12,059)
Benefit plans adjustment	(218,595)	—
Unrealized (loss) gain on investments	(580)	10,063
Unrealized losses on cash flow hedges	(16,391)	(13,795)
	\$ 1,828	\$(28,808)

The change in Accumulated other comprehensive income (loss) consists of other comprehensive income (loss) of \$240,331, offset by the SFAS No. 158 adjustments of \$209,695.

The income tax provision (benefit) recorded in fiscal years 2007 and 2006 for the unrealized gains on investments was \$(6,524) and \$743, respectively. The income tax benefit recorded in fiscal years 2007 and 2006 for cash flow hedges was \$1,247 and \$800, respectively. The income tax provision recorded in fiscal years 2007 and 2006 for the minimum pension liability adjustment was \$2,050 and \$47,259, respectively. Income taxes are generally not provided for translation adjustments.

The unrealized losses on cash flow hedges included in other comprehensive income (loss) for 2007 and 2006 are net of reclassification adjustments of \$5,099 and \$2,645, net of tax, respectively, for realized net hedge losses recorded to revenues. These amounts had been included in Accumulated other comprehensive income (loss) in prior periods. The tax benefits associated with these reclassification adjustments in 2007 and 2006 were \$3,126 and \$1,621, respectively.

12 Commitments and Contingencies

Commitments

Rental expense for all operating leases amounted to \$68,100 in 2007, \$63,400 in 2006, and \$59,000 in 2005. Future minimum rental commitments on noncancelable leases are as follows: 2008—\$45,600; 2009—\$34,200; 2010—\$25,200; 2011—\$18,300; 2012—\$14,100 and an aggregate of \$16,200 thereafter.

As of September 30, 2007, the Company has certain future purchase commitments aggregating to approximately \$365,000, which will be expended over the next several years.

Contingencies

The Company is named as a defendant in five purported class action suits brought on behalf of direct purchasers of the Company's products, such as distributors, alleging that the Company violated federal antitrust laws, resulting in the charging of higher prices for the Company's products to the plaintiff and other purported class members. The cases filed are as follows: *Louisiana Wholesale Drug Company, Inc., et. al. vs. Becton Dickinson and Company* (Civil Action No. 05-1602, U.S. District Court, Newark, New Jersey), filed on March 25, 2005; *SAJ Distributors, Inc. et. al. vs. Becton Dickinson & Co.* (Case 2:05-CV-04763-JD, United States District Court, Eastern District of Pennsylvania), filed on September 6, 2005; *Dik Drug Company, et. al. vs. Becton, Dickinson and Company* (Case No. 2:05-CV-04465, U.S. District Court, Newark, New Jersey), filed on September 12, 2005; *American Sales Company, Inc. et. al. vs. Becton, Dickinson & Co.* (Case No. 2:05-CV-05212-CRM, U.S. District Court, Eastern District of Pennsylvania), filed on October 3, 2005; and *Park Surgical Co. Inc. et. al. vs. Becton, Dickinson and Company* (Case 2:05-CV-05678-CMR, United States District Court, Eastern District of Pennsylvania), filed on October 26, 2005.

The actions brought by Louisiana Wholesale Drug Company and Dik Drug Company in New Jersey have been consolidated under the caption "*In re Hypodermic Products Antitrust Litigation.*"

The Company is also named as a defendant in four purported class action suits brought on behalf of indirect purchasers of the Company's products, alleging that the Company violated federal antitrust laws, resulting in the charging of higher prices for the Company's products to the plaintiff and other purported class members. The cases filed are as follows: *Jabo's Pharmacy, Inc., et. al. v. Becton Dickinson & Company* (Case No. 2:05-CV-00162, United States District Court, Greenville, Tennessee) filed on June 7, 2005; *Drug Mart Tallman, Inc., et. al. v. Becton Dickinson and Company* (Case No. 2:06-CV-00174, U.S. District Court, Newark, New Jersey), filed on January 17, 2006;

Medstar v. Becton Dickinson (Case No. 06-CV-03258-JLL (RJH), U.S. District Court, Newark, New Jersey), filed on May 18, 2006; and *The Hebrew Home for the Aged at Riverdale v. Becton Dickinson and Company* (Case No. 07-CV-2544, U.S. District Court, Southern District of New York), filed on March 28, 2007. A fifth purported class action on behalf of indirect purchasers (*International Multiple Sclerosis Management Practice v. Becton Dickinson & Company* (Case No. 2:07-cv-10602, U.S. District Court, Newark, New Jersey), filed on April 5, 2007) was voluntarily withdrawn by the plaintiff.

The plaintiffs in each of the antitrust class action lawsuits seek monetary damages. All of the antitrust class action lawsuits have been consolidated for pre-trial purposes in a Multi-District Litigation (MDL) in federal court in New Jersey.

On August 31, 2005, Daniels Sharpsmart filed suit against the Company, another manufacturer and three group purchasing organizations under the caption *Daniels Sharpsmart, Inc. v. Tyco International, (US) Inc., et. al.* (Civil Action No. 505CV169, United States District Court, Eastern District of Texas). The plaintiff alleged, among other things, that the Company and the other defendants conspired to exclude the plaintiff from the sharps-collection market by entering into long-term contracts in violation of federal and state antitrust laws, and sought monetary damages. On September 28, 2007, the Company and the plaintiff entered into an agreement to settle the matter on terms that are not material to the Company.

On June 6, 2006, UltiMed, Inc., a Minnesota company, filed suit against the Company in the United States District Court in Minneapolis, Minnesota (*UltiMed, Inc. v. Becton, Dickinson and Company* (06CV2266)). The plaintiff alleges, among other things, that the Company excluded the plaintiff from the market for home use insulin syringes by entering into anticompetitive contracts in violation of federal and state antitrust laws. The plaintiff seeks money damages and injunctive relief.

In June 2007, Retractable Technologies, Inc. ("plaintiff") filed a complaint against the Company under the caption *Retractable Technologies, Inc. vs. Becton Dickinson and Company* (Civil Action No. 2:07-cv-250, United States District Court, Eastern District of Texas). Plaintiff alleges that the *BD Integra* syringes infringe patents licensed exclusively to the plaintiff. This patent claim was not covered by the release contained in the July 2004 settlement agreement between the Company and plaintiff to settle the lawsuit previously filed by plaintiff. In its complaint, plaintiff also alleges that the Company engaged in false advertising with respect to certain of the Company's safety-engineered products in violation of the Lanham Act; acted to exclude the plaintiff from various product markets and to maintain its market share through, among other things, exclusionary contracts in violation of state and Federal antitrust laws; and engaged in

unfair competition. The non-patent claims purport to relate to actions allegedly taken by the Company following the date of the July 2004 settlement agreement referenced above. Plaintiff seeks treble damages, attorney's fees and injunctive relief.

The Company, along with another manufacturer and several medical product distributors, is named as a defendant in three product liability lawsuits relating to healthcare workers who allegedly sustained accidental needlesticks, but have not become infected with any disease. Generally, these actions allege that healthcare workers have sustained needlesticks using hollow-bore needle devices manufactured by the Company and, as a result, require medical testing, counseling and/or treatment. In some cases, these actions additionally allege that the healthcare workers have sustained mental anguish. Plaintiffs seek money damages in all of these actions. The Company had previously been named as a defendant in eight similar suits relating to healthcare workers who allegedly sustained accidental needlesticks, each of which has either been dismissed with prejudice or voluntarily withdrawn. Regarding the three pending suits:

- In Ohio, *Grant vs. Becton Dickinson et. al.* (Case No. 98CVB075616, Franklin County Court), on September 21, 2006, the Ohio Court of Appeals reversed the trial court's grant of class certification. The matter has been remanded to the trial court for a determination of whether the class can be redefined.
- In Oklahoma and South Carolina, cases have been filed on behalf of an unspecified number of healthcare workers seeking class action certification under the laws of these states in state court in Oklahoma, under the caption *Palmer vs. Becton Dickinson et. al.* (Case No. CJ-98-685, Sequoyah County District Court), filed on October 27, 1998, and in state court in South Carolina, under the caption *Bales vs. Becton Dickinson et. al.* (Case No. 98-CP-40-4343, Richland County Court of Common Pleas), filed on November 25, 1998.

The Company continues to oppose class action certification in these cases, including pursuing all appropriate rights of appeal.

The Company, along with a number of other manufacturers, was named as a defendant in approximately 524 product liability lawsuits in various state and Federal courts related to natural rubber latex gloves which the Company ceased manufacturing in 1995. Cases pending in Federal court are being coordinated under the matter *In re Latex Gloves Products Liability Litigation* (MDL Docket No. 1148) in Philadelphia, and analogous procedures have been implemented in the state courts of California, Pennsylvania, New Jersey and New York. Generally, these actions allege that medical personnel have suffered allergic reactions ranging from skin irritation to anaphylaxis as a result of exposure to medical gloves containing

natural rubber latex. Since the inception of this litigation, 467 of these cases have been closed with no liability to the Company, and 46 cases have been settled for an aggregate de minimis amount.

On August 8, 2005, the Company received a subpoena issued by the Attorney General of the State of Connecticut, which seeks documents and information relating to the Company's participation as a member of Healthcare Research & Development Institute, LLC ("HRDI"), a healthcare trade organization. The subpoena indicated that it was issued as part of an investigation into possible violations of the antitrust laws. On August 21, 2006, the Company received a subpoena issued by the Attorney General of the State of Illinois which sought documents and information relating to the Company's participation as a member of HRDI. The subpoena indicated that it was issued as part of an investigation into possible violations of the Illinois Consumer Fraud and Deceptive Business Practices Act, Charitable Trust Act, and Solicitation for Charity Act. An independent member of the Company's board of directors, Gary Mecklenburg, also served as a member and the non-executive chairman of HRDI until November 5, 2006. In January 2007, it was reported that HRDI entered into a settlement with the Attorneys General of Connecticut and Florida with respect to the investigation being conducted by the Connecticut Attorney General (the Company has not been contacted by the State of Florida). To the Company's knowledge, both the Connecticut and Illinois investigations are still ongoing. The Company believes that its participation in HRDI complied fully with the law and has responded to these subpoenas. The Company has not received any communication with respect to either investigation since completing its document production.

On May 28, 2004, Therasense, Inc. ("Therasense") filed suit against the Company in the U.S. District Court for the Northern District of California (Case Number: C 04-02123 WDB) asserting that the Company's blood glucose monitoring products infringe certain Therasense patents. On August 10, 2004, in response to a motion filed by Therasense in the U.S. District Court for the District of Massachusetts, the court transferred to the court in California an action previously filed by the Company against Therasense requesting a declaratory judgment that the Company's products do not infringe the Therasense patents and that the Therasense patents are invalid.

As was previously reported, Becton Dickinson France, S.A., a subsidiary of the Company, was listed among approximately 2,200 other companies in an October 2005 report of the Independent Inquiry Committee ("IIC") of the United Nations ("UN") as having been involved in humanitarian contracts in which unauthorized payments were suspected of having been made to the Iraqi Government in connection with the UN's Oil-for-Food Programme (the "Programme"). The Company conducted an internal review and found no evidence that the

Company or any employee or representative of the Company made, authorized, or approved improper payments to the Iraqi Government in connection with the Programme. The Company reported the results of its internal review to the Vendor Review Committee of the United Nations Procurement Service. In May 2007, the French Judicial Police conducted searches of the Company's offices in France with respect to the matters that were the subject of the 2005 IIC report. The Company was informed that it is one of a number of companies named in the IIC report that is being investigated by the French Judicial Police. The Company is cooperating fully with the investigation.

In July 2007, the Company received notice of a suit instituted in Saudi Arabia by El Seif Development ("El Seif"), a former distributor of the Company (Case No. 7516, Board of Grievances, Saudi Arabia). El Seif seeks monetary damages arising out of the termination of its distributor agreement and other contractual arrangements with the Company.

The Company has been served with a qui tam complaint filed by a private party against the Company in the United States District Court, Northern District of Texas, alleging violations of the Federal False Claims Act ("FCA") and the Texas False Claims Act (the "TFCA"). Under the FCA, the United States Department of Justice, Civil Division has a certain period of time in which to decide whether to join the claim against the Company as an additional plaintiff; if not, the private plaintiff is free to pursue the claim on its own. A similar process is followed under the TFCA. To the Company's knowledge, no decision has yet been made by the Civil Division or the State of Texas whether to join this claim.

The Company believes that it has meritorious defenses to each of the above-mentioned suits pending against the Company and is engaged in a vigorous defense of each of these matters.

The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business.

The Company is a party to a number of Federal proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as "Superfund," and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are commencing. For all sites, there are other potentially responsible parties that may be jointly or severally liable to pay all cleanup costs.

Given the uncertain nature of litigation generally, the Company is not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. generally accepted accounting principles, the Company establishes accruals to the extent probable future

losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, excess liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company's consolidated results of operations and consolidated cash flows.

13 Share-Based Compensation

The Company grants share-based awards under the 2004 Employee and Director Equity-Based Compensation Plan ("2004 Plan"), which provides for long-term incentive compensation to employees and directors consisting of: stock appreciation rights ("SARs"), stock options, performance-based restricted stock units, time-vested restricted stock units and other stock awards. The Company believes such awards align the interest of its employees and directors with those of its shareholders. Prior to the adoption of the 2004 Plan, the Company had employee and director stock option plans, which were terminated with respect to future grants effective upon shareholder approval of the 2004 Plan in February 2004. In 2007, 2006 and 2005, the compensation expense for these plans charged to income was \$107,706, \$108,613 and \$70,199, respectively, and the associated income tax benefit recognized was \$37,179, \$35,155 and \$19,941, respectively.

Stock Appreciation Rights

Beginning with the annual share-based grant in November 2005, the Company granted SARs and discontinued the issuance of stock options. SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs vest over a four-year period and have a ten-year term, similar to the previously granted stock options. The fair value was estimated on the date of grant using a lattice-based binomial option valuation model that uses the following weighted-average assumptions in 2007 and 2006: risk-free interest rate of 4.56% and 4.48%, respectively; expected volatility of 28% for both years; expected dividend yield of 1.37% and 1.46%, respectively, and expected life of 6.5 years for both years. Expected volatility is based upon historical volatility for the Company's common stock and other factors.

The expected term of SARs granted is derived from the output of the model, using assumed exercise rates based on historical exercise and termination patterns, and represents the period of time that options granted are expected to be outstanding. The risk-free interest rate used is based upon the published U.S. Treasury yield curve in effect at the time of grant for instruments with a similar life. The dividend yield is based upon the most recently declared quarterly dividend as of the grant date. The weighted average grant date fair value of SARs granted during 2007 and 2006 was \$22.66 and \$18.43, respectively. The total intrinsic value of SARs exercised during 2007 was \$321. The Company issued 3,192 shares during 2007 to satisfy the SARs exercised.

A summary of SARs outstanding as of September 30, 2007, and changes during the year then ended is as follows:

	SARs	Weighted Average Grant Date Fair Value	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance at October 1	1,684,541	\$59.16		
Granted	1,570,336	71.75		
Exercised	(18,882)	59.16		
Forfeited, canceled or expired	(71,266)	65.62		
Balance at September 30	3,164,729	\$65.26	8.63	\$53,137
Vested and expected to vest at September 30	2,896,169	\$65.17	8.62	\$48,885
Exercisable at September 30	479,130	\$59.90	8.20	\$10,613

Stock Options

All stock option grants are for a ten-year term. Stock options issued after November 2001 vest over a four-year period. Stock options issued prior to November 2001 vested over a three-year period. Stock options granted in 2005 were valued based on the grant date fair value of those awards, using a lattice-based binomial option valuation model that used the following weighted-average assumptions: risk-free interest rate of 3.93%; expected volatility of 29%; expected dividend yield of 1.28% and expected life of 6.5 years.

The weighted average grant date fair value of stock options granted during 2005 was \$17.16.

A summary of stock options outstanding as of September 30, 2007, and changes during the year then ended is as follows:

	Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance at October 1	18,253,990	\$34.90		
Granted	—	—		
Exercised	(4,213,955)	31.83		
Forfeited, canceled or expired	(42,288)	39.70		
Balance at September 30	13,997,747	\$35.81	4.75	\$647,241
Vested and expected to vest at September 30	13,826,293	\$35.68	4.73	\$641,058
Exercisable at September 30	12,283,204	\$34.39	4.49	\$585,412

Cash received from the exercising of stock options in 2007, 2006 and 2005 was \$134,133, \$147,831 and \$123,613, respectively. The actual tax benefit realized for tax deductions from stock option exercises totaled \$59,491, \$48,751 and \$44,958, respectively. The total intrinsic value of stock options exercised during the years 2007, 2006 and 2005 was \$187,537, \$168,752 and \$134,342, respectively.

Performance-Based Restricted Stock Units

Performance-based restricted stock units cliff vest three years after the date of grant. These units are tied to the Company's performance against pre-established targets, including its average growth rate of consolidated revenues and average return on invested capital, over a three-year performance period. Under the Company's long-term incentive program, the actual payout under these awards may vary from zero to 250% of an employee's target payout, based on the Company's actual performance over the three-year performance period. The fair value is based on the market price of the Company's stock on the date of grant. Compensation cost initially recognized assumes that the target payout level will be achieved and is adjusted for subsequent changes in the expected outcome of performance-related conditions.

A summary of performance-based restricted stock units outstanding as of September 30, 2007, and changes during the year then ended is as follows:

	Stock Units	Weighted Average Grant Date Fair Value
Balance at October 1	3,013,113	\$54.62
Granted	1,210,648	71.72
Vested	(120,923)	39.71
Forfeited or canceled	(218,883)	57.84
Balance at September 30 ^(A)	3,883,955	\$60.23
Expected to vest at September 30 ^(B)	1,954,149	\$58.11

(A) Based on 250% of the target payout.

(B) Net of expected forfeited units and units in excess of the expected performance payout of 241,858 and 1,687,948, respectively.

The weighted average grant date fair value of performance-based restricted stock units granted during the years 2006 and 2005 was \$59.16 and \$54.41, respectively. At September 30, 2007, the weighted average remaining contractual term of performance-based restricted stock units is 1.10 years.

Time-Vested Restricted Stock Units

Time-vested restricted stock units generally cliff vest three years after the date of grant, except for certain key executives of the Company, including the executive officers, for which such units generally vest one year following the employee's retirement. The related share-based compensation expense is recorded over the requisite service period, which is the vesting period or in the case of certain key executives is based on retirement eligibility. The fair value of all time-vested restricted stock units is based on the market value of the Company's stock on the date of grant.

A summary of time-vested restricted stock units outstanding as of September 30, 2007, and changes during the year then ended is as follows:

	Stock Units	Weighted Average Grant Date Fair Value
Balance at October 1	1,166,718	\$55.95
Granted	540,853	72.20
Vested	(42,944)	55.83
Forfeited or canceled	(46,545)	72.03
Balance at September 30	1,618,082	\$61.11
Expected to vest at September 30	1,456,274	\$61.11

The weighted average grant date fair value of time-vested restricted stock units granted during the years 2006 and 2005 was \$59.62 and \$54.48, respectively. At September 30, 2007, the weighted average remaining contractual term of the time-vested restricted stock units is 2.03 years.

The amount of unrecognized compensation expense for all non-vested share-based awards as of September 30, 2007, is approximately \$108.4 million, which is expected to be recognized over a weighted-average remaining life of approximately 1.95 years. At September 30, 2007, 6,420,643 shares were authorized for future grants under the 2004 Plan.

The Company has a policy of satisfying share-based payments through either open market purchases or shares held in treasury. At September 30, 2007, the Company has sufficient shares held in treasury to satisfy these payments in 2008.

Other Stock Plans

The Company has a Stock Award Plan, which allows for grants of common shares to certain key employees. Distribution of 25% or more of each award is deferred until after retirement or involuntary termination, upon which the deferred portion of the award is distributable in five equal annual installments. The balance of the award is distributable over five years from the grant date, subject to certain conditions. In February 2004, this plan was terminated with respect to future grants upon the adoption of the 2004 Plan. At September 30, 2007 and 2006, awards for 214,206 and 270,762 shares, respectively, were outstanding.

The Company has a Restricted Stock Plan for Non-Employee Directors which reserves for issuance of 300,000 shares of the Company's common stock. No restricted shares were issued in 2007.

The Company has a Directors' Deferral Plan, which provides a means to defer director compensation, from time to time, on a deferred stock or cash basis. As of September 30, 2007, 117,044 shares were held in trust, of which 3,466 shares represented Directors' compensation in 2007, in accordance with the provisions of the plan. Under this plan, which is unfunded, directors have an unsecured contractual commitment from the Company.

The Company also has a Deferred Compensation Plan that allows certain highly-compensated employees, including executive officers, to defer salary, annual incentive awards and certain equity-based compensation. As of September 30, 2007, 265,846 shares were issuable under this plan.

14 Earnings per Share

The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows:

	2007	2006	2005
Average common shares outstanding	244,929	247,067	251,429
Dilutive share equivalents from share-based plans	9,881	9,487	9,283
Average common and common equivalent shares outstanding—assuming dilution	254,810	256,554	260,712

15 Segment Data

The Company's organizational structure is based upon its three principal business segments: BD Medical ("Medical"), BD Diagnostics ("Diagnostics") and BD Biosciences ("Biosciences").

The principal product lines in the Medical segment include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefilled drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; sharps disposal containers; and home healthcare products. The principal products and services in the Diagnostics segment include integrated systems for specimen collection; an extensive line of safety-engineered specimen blood collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and healthcare-associated infections; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; and rapid diagnostic assays. The principal product lines in the Biosciences segment include fluorescence activated cell sorters and analyzers; cell imaging systems; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; cell culture media supplements for biopharmaceutical manufacturing; and diagnostic assays.

The Company evaluates performance of its business segments based upon operating income. Segment operating income represents revenues reduced by product costs and operating expenses.

Distribution of products is primarily through independent sales representatives, independent distribution channels, and directly to other end-users. Sales to a distributor that supplies products from the Medical and Diagnostics segments accounted for approximately 9% of revenues in 2007, and 11% of revenues in 2006 and 2005, respectively. No other customer accounted for 10% or more of revenues in any of the three years presented.

Revenues ^(A)	2007	2006	2005
Medical	\$3,420,670	\$3,106,646	\$2,884,240
Diagnostics	1,905,105	1,715,090	1,632,260
Biosciences	1,033,933	916,281	824,333
	\$6,359,708	\$5,738,017	\$5,340,833

Segment Operating Income

Medical	\$ 971,990	\$ 864,180	\$ 747,777
Diagnostics	342,778 ^(B)	390,355 ^(B)	403,420
Biosciences	258,806 ^(B)	221,925	185,827
Total Segment Operating Income	1,573,574	1,476,460	1,337,024
Unallocated Expenses ^(C)	(369,629)	(350,558)	(299,495)
Income From Continuing Operations			
Before Income Taxes	\$1,203,945	\$1,125,902	\$1,037,529

Segment Assets

Medical	\$3,289,490	\$2,835,613	\$2,656,320
Diagnostics	1,843,654	1,485,959	1,245,769
Biosciences	817,000	727,634	678,286
Total Segment Assets	5,950,144	5,049,206	4,580,375
Corporate and All Other ^(D)	1,379,221	1,775,319	1,552,418
	\$7,329,365	\$6,824,525	\$6,132,793

Capital Expenditures

Medical	\$ 352,696	\$ 268,669	\$ 182,737
Diagnostics	113,691	104,815	99,742
Biosciences	73,502	38,952	22,218
Corporate and All Other	16,505	44,631	11,143
	\$ 556,394	\$ 457,067	\$ 315,840

Depreciation and Amortization

Medical	\$ 223,430	\$ 210,044	\$ 197,998
Diagnostics	138,936	116,072	102,882
Biosciences	68,889	63,383	64,599
Corporate and All Other	10,086	12,833	17,190
	\$ 441,341	\$ 402,332	\$ 382,669

(A) Intersegment revenues are not material.

(B) Includes the acquired in-process research and development charges in 2007 related to the TriPath and Plasco acquisitions, and in 2006 related to the GeneOhm acquisition, as discussed in Note 3.

(C) Includes primarily share-based compensation expense; interest, net; foreign exchange; and corporate expenses.

(D) Includes cash and investments and corporate assets.

Revenues by Organizational Units	2007	2006	2005
BD Medical			
Medical Surgical Systems	\$1,864,080	\$1,748,743	\$1,661,150
Diabetes Care	695,981	656,533	600,172
Pharmaceutical Systems	791,900	639,694	563,271
Ophthalmic Systems	68,709	61,676	59,647
	\$3,420,670	\$3,106,646	\$2,884,240
BD Diagnostics			
Preanalytical Systems	\$1,006,692	\$ 927,759	\$ 854,831
Diagnostic Systems	898,413	787,331	777,429
	\$1,905,105	\$1,715,090	\$1,632,260
BD Biosciences			
Immunocytometry Systems	\$ 588,401	\$ 502,847	\$ 452,383
Discovery Labware	277,902	256,085	231,365
Pharmingen	167,630	157,349	140,585
	\$1,033,933	\$ 916,281	\$ 824,333
	\$6,359,708	\$5,738,017	\$5,340,833

Geographic Information

The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico), Europe, and Other, which is composed of Canada, Latin America, Japan and Asia Pacific.

Revenues to unaffiliated customers are based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.

	2007	2006	2005
Revenues			
United States	\$3,033,005	\$2,739,344	\$2,521,672
Europe	2,047,388	1,762,782	1,670,963
Other	1,279,315	1,235,891	1,148,198
	\$6,359,708	\$5,738,017	\$5,340,833
Long-Lived Assets			
United States	\$2,172,327	\$1,934,994	\$1,687,808
Europe	1,106,284	893,495	823,694
Other	646,188	540,925	424,165
Corporate	274,000	269,858	221,812
	\$4,198,799	\$3,639,272	\$3,157,479

Quarterly Data (unaudited)

Thousands of dollars, except per share amounts

	2007				
	1st	2nd	3rd	4th	Year
Revenues	\$1,501,526	\$1,575,922	\$1,631,159	\$1,651,101	\$6,359,708
Gross Profit	792,593	811,382	840,088	843,724	3,287,787
Income from Continuing Operations	131,051 ^(B)	235,539	240,469 ^(B)	249,108	856,167 ^(B)
Earnings per Share:					
Income from Continuing Operations	.53	.96	.98	1.02	3.50
Income from Discontinued Operations	.05	.03	.02	.04	.14
Basic Earnings per Share	.58	.99	1.00	1.07	3.63
Income from Continuing Operations	.51	.92	.95	.98	3.36
Income from Discontinued Operations	.05	.03	.02	.04	.13
Diluted Earnings per Share ^(A)	.56	.95	.96	1.03	3.49
2006					
	1st	2nd	3rd	4th	Year
Revenues	\$1,393,845	\$1,424,209	\$1,457,347	\$1,462,616	\$5,738,017
Gross Profit	727,899	725,443	737,832	753,578	2,944,752
Income from Continuing Operations	223,702	163,458 ^(C)	211,070	216,880	815,110 ^(C)
Earnings per Share:					
Income from Continuing Operations	.90	.66	.86	.88	3.30
Loss from Discontinued Operations	(.02)	(.04)	(.02)	(.17) ^(D)	(.25) ^(D)
Basic Earnings per Share ^(A)	.88	.62	.84	.71	3.04
Income from Continuing Operations	.87	.63	.83	.85	3.18
Loss from Discontinued Operations	(.02)	(.04)	(.02)	(.17) ^(D)	(.24) ^(D)
Diluted Earnings per Share ^(A)	.85	.60	.81	.68	2.93

(A) Total per share amounts may not add due to rounding.

(B) Includes the acquired in-process research and development charges in the first and third quarters related to the TriPath and Plasco acquisitions, respectively, as discussed in Note 3.

(C) Includes the acquired in-process research and development charge related to the GeneOhm acquisition, as discussed in Note 3.


(D) Includes the impact of the BGM exit costs, as discussed in Note 3.

The graph below presents a comparison of cumulative total return to shareholders for the five-year period ended September 30, 2007 for BD, the S&P 500 Index and the S&P 500 Health Care Equipment Index.

Cumulative total return to shareholders is measured by dividing total dividends (assuming dividend reinvestment) plus per share price change for the period by the share

price at the beginning of the measurement period. BD's cumulative shareholder return is based on an investment of \$100 on September 30, 2002 and is compared to the cumulative total return of the S&P 500 Index and the S&P 500 Healthcare Equipment Index over the same period with a like amount invested.

COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN AMONG BECTON, DICKINSON AND COMPANY, THE S&P 500 INDEX AND THE S&P HEALTH CARE EQUIPMENT INDEX*



*Source: Standard & Poor's

Annual Meeting

1:00 p.m.
Tuesday, January 29, 2008
Hilton Short Hills
41 John F. Kennedy Parkway
Short Hills, NJ 07078

This annual report is not a solicitation of proxies.

Direct Stock Purchase Plan

The Direct Stock Purchase Plan established through Computershare Trust Company, N.A., enhances the services provided to existing shareholders and facilitates initial investments in BD shares. Plan documentation and additional information may be obtained by calling Computershare Trust Company, N.A., at 1-877-498-8861, or by accessing the "Buy Shares" feature located within the Investor Centre of Computershare's website at www.computershare.com.

NYSE Symbol

BDX

On February 22, 2007, Edward J. Ludwig, Chairman, President and Chief Executive Officer, submitted to the NYSE the Written Affirmation required by the rules of the NYSE certifying that he was not aware of any violations by BD of NYSE Corporate Governance listing standards.

The certifications of Mr. Ludwig and John R. Considine, Senior Executive Vice President and Chief Financial Officer, made pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 regarding the quality of BD's public disclosure, have been filed as exhibits to the Company's 2007 Annual Report on Form 10-K.

Transfer Agent and Registrar

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
Phone: 1-877-498-8861
International: 1-781-575-2726
Internet: www.computershare.com

Common Stock Prices and Dividends (per common share)

By Quarter	2007		
	High	Low	Dividends
First	\$73.79	\$68.81	\$0.245
Second	78.14	69.85	0.245
Third	80.87	73.65	0.245
Fourth	82.61	74.24	0.245
By Quarter	2006		
	High	Low	Dividends
First	\$60.72	\$50.07	\$0.215
Second	65.76	58.97	0.215
Third	65.28	58.31	0.215
Fourth	70.67	58.84	0.215

Shareholder Information

At November 14, 2007, BD had approximately 8,862 shareholders of record. BD's Statement of Corporate Governance Principles, BD's Business Conduct and Compliance Guide, the charters of BD's Committees of the Board of Directors, BD's reports and statements filed with or furnished to the Securities and Exchange Commission and other information are posted on BD's website at www.bd.com/investors/.

Shareholders may receive, without charge, printed copies of these documents, including BD's 2007 Annual Report on Form 10-K, by contacting:

Investor Relations
BD
1 Becton Drive
Franklin Lakes, NJ 07417-1880
Phone: 1-800-284-6845
Internet: www.bd.com

Independent Auditors

Ernst & Young LLP
5 Times Square
New York, NY 10036-6530
Phone: 1-212-773-3000
Internet: www.ey.com

The trademarks indicated by italics are the property of Becton, Dickinson and Company, its subsidiaries or related companies. All other brands are trademarks of their respective owners.

Certain BD Biosciences products are intended for research use only, and not for use in diagnostic or therapeutic procedures. ©2007 BD

Reconciliations to adjusted amounts (in millions)	2007	2006
Operating income	\$1,203	\$1,141
Acquired in-process R&D	122	53
Insurance settlement	—	(17)
Operating income—adjusted	\$1,325	\$1,178
% change from 2006	13%	
as a % of revenues	20.8%	20.5%
Amounts may not add due to rounding.		

Corporate Officers

Edward J. Ludwig

Chairman, President and
Chief Executive Officer

Richard K. Berman

Vice President and Treasurer

Donna M. Boles

Senior Vice President – Human Resources

Mark H. Borofsky

Vice President – Taxes

James R. Brown

Vice President – Quality Management

Scott P. Bruder, M.D., Ph.D.

Senior Vice President and
Chief Technology Officer

Gary M. Cohen

Executive Vice President

John R. Considine

Senior Executive Vice President and
Chief Financial Officer

Helen Cuniff

President – Asia-Pacific

Jean-Marc Dageville

President – Western Europe

David T. Durack, M.D.

Senior Vice President – Corporate
Medical Affairs

Vincent A. Forlenza

Executive Vice President

A. John Hanson

Executive Vice President

Laureen Higgins

President – North Latin America

David W. Highet

Vice President and Chief Intellectual
Property Counsel

William A. Kozy

Executive Vice President

Dean J. Paranicas

Vice President, Corporate Secretary and
Public Policy

Carmelo Sanz de Barros

President – Latin America

Jeffrey S. Sherman

Senior Vice President and General Counsel

Patricia B. Shrader

Senior Vice President, Corporate Regulatory
and External Affairs

William A. Tozzi

Vice President – Finance

Board of Directors

Basil L. Anderson^{1,2,6}

Retired Vice Chairman – Staples, Inc.

Henry P. Becton, Jr.^{2,5,6}

Vice Chairman and former President – WGBH
Educational Foundation

Edward F. DeGraan^{1,2,4}

Retired Vice Chairman – Gillette
Procter & Gamble Company

Claire M. Fraser-Liggett, Ph.D.^{3,6}

Director – Institute of Genome Sciences,
University of Maryland School of Medicine

Marshall O. Larsen^{1,2}

Chairman, President and Chief Executive
Officer – Goodrich Corporation

Edward J. Ludwig⁵

Chairman, President and
Chief Executive Officer – BD

Adel A. F. Mahmoud, M.D., Ph.D.^{3,6}

Professor, Department of Molecular Biology
and the Woodrow Wilson School of Public
and International Affairs – Princeton University

Gary A. Mecklenburg^{1,4}

Retired President and Chief Executive Officer –
Northwestern Memorial HealthCare

Cathy E. Minehan^{1,3}

Retired President and Chief Executive Officer –
Federal Reserve Bank of Boston

James F. Orr^{1,2,5}

Chairman and retired Chief Executive
Officer – Convergys Corporation

Willard J. Overlock, Jr.^{2,5,6}

Retired Partner – Goldman, Sachs & Co.

James E. Perrella^{3,4,5}

Retired Chairman – Ingersoll-Rand Company

Bertram L. Scott^{1,3,4}

Executive Vice President – TIAA-CREF

Alfred Sommer, M.D., M.H.S.^{3,4}

Professor of International Health,
Epidemiology and Ophthalmology –
Johns Hopkins University Medical School
and Bloomberg School of Public Health

Committees appointed by the Board of Directors

1 – Audit Committee

2 – Compensation and Benefits Committee

3 – Corporate Affairs Committee

4 – Corporate Governance and Nominating Committee

5 – Executive Committee

6 – Finance Committee



Seated, left to right are: James E. Perrella and Willard J. Overlock, Jr. Standing left to right are: Basil L. Anderson; James F. Orr; Marshall O. Larsen; Cathy E. Minehan; Adel A. F. Mahmoud, M.D., Ph.D.; Alfred Sommer, M.D., M.H.S.; Edward J. Ludwig; Henry P. Becton, Jr.; Bertram L. Scott; Claire M. Fraser-Liggett, Ph.D.; Edward F. DeGraan; and Gary A. Mecklenburg.



Mixed Sources

Product group from well-managed forests, controlled sources and recycled wood or fiber

www.fsc.org Cert no. SG5-COC-3028
© 1996 Forest Stewardship Council



BD

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com